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Chapter 1 
General Introduction 
 
 
1.1. Cardiac Function 
For the management of a broad range of heart diseases, a quantitative, reproducible 
approach for the assessment of cardiac (dys-) function is of great importance. However, 
cardiac (dys-) function is a very general and non-specific entity that is defined depending on 
the context. This makes it difficult to unambiguously define, and thus quantify, (dys-) function 
in a clinical context. Intrinsic cardiac function implies the assessment of true contractility of 
the myocardium. Using non-invasive approaches, this is currently not measurable and in 
clinical practice surrogates for true cardiac contractility are assessed and reported as 
reflecting cardiac function.  
Figure 1.1 gives an overview of an integrated view on ‘cardiac function’. First of all, two 
different levels are distinguished: intrinsic myocyte function (often referred to as contractility) 
and ventricular pump function. At both levels, function consists of two components, namely 
force development (resulting in the generation of sufficient pressure to open the cardiac 
valves) and deformation (resulting in volume ejection). Additionally, ventricular function can 
be interpreted either from a global perspective as overall pump performance, or from a 
regional perspective where the contributions of individual wall segments are taken into 
account. The interactions between the components force development and deformation is 
determined by the boundary conditions in which the heart functions. These include: a) wall 
properties such as tissue composition/elasticity, fibre structure and global geometry, which 
determine the local segment interactions and the resulting wall stress; b) interaction between 
the heart and peripheral circulation, mostly described as (pressure & volume) loading 
conditions. 
In summary, cardiac function can qualitatively be defined as the ability of the myocardium 
to work (pump) and keep on working sufficiently in order to maintain an adequate stroke 
volume (as demanded by the peripheral organs) by developing force to generate pressure 
and by deforming to displace volume.   
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Figure 1.1: An integrated view on cardiac function. 
 
1.2. Cardiac Remodelling 
Ventricular remodelling is an adaptive mechanism used by the ventricle to cope with a 
problem, either within the myocardium itself or the environment it has to work in, intended to 
generate sufficient cardiac output to fulfil the needs of the body (figure 1.2). However, since 
this is an abnormal situation with inherent disadvantages, on the long term it will lead to 
irreversible damage to the myocardium which can evolve into ventricular dysfunction and 
heart failure.  
Reduced
contractility
Increased
(pressure)
loading
Unstable condition Unstable conditionRemodelling
Balance = stable condition
 
Figure 1.2: Balance of cardiac contractility and loading. 
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Several cardiac conditions are associated with progressive remodelling of the ventricle. 
Examples of this are pressure or volume overload due to valvular stenosis or regurgitation, 
ischaemic remodelling in coronary artery disease, pressure remodelling in severe 
hypertension, electrical remodelling in certain conduction abnormalities (e.g. LBBB), genetic 
abnormalities resulting in progressive development of local hypertrophy and fibrosis etc.  
Most non-ischemic remodelling, like left ventricular hypertrophy (LVH), has classically 
been considered as a substrate affecting the ventricle globally. However, it has been shown 
that e.g. arterial hypertension results in localised LVH due to regional differences in wall 
stress, suggesting that regional phenomena might play a more important role than previously 
assumed. This implies that enhanced understanding of LV remodelling might still lead to 
optimized clinical treatment of these patients.  
For the clinical evaluation of patients with signs of ventricular remodelling, a good method 
for the evaluation and follow up of the evolution of intrinsic ventricular function is required. 
This is however hampered by two factors: both the abnormal loading and the altered 
geometry associated with several of these heart diseases importantly affect the current 
methods used to evaluate cardiac function. To study cardiac function in the context of 
ventricular remodelling, techniques which are as load-independent as possible are required 
since pressure or volume loading will mostly be abnormal. In clinical routine, indirect 
measurements of contractility and volume ejection are being used, mainly based on non-
invasive imaging techniques (echocardiography, cardiac magnetic resonance imaging (CMR) 
or computed tomography (CT)). 
 
 
1.3. Aims and Outline of the Thesis 
The main aim of this thesis was to study cardiac function in different types of myocardial 
remodelling. We sought to follow these objectives:  
  
• To describe the impact of Velocity and deformation imaging on the assessment of 
myocardial dysfunction. Chapter 2 addresses the assessment of cardiac function, 
myocardial motion and deformation as well as clinical applications of Velocity and 
deformation imaging.  
 
• To propose a novel method for Doppler signal analysis. Chapter 3 describes the 
method underlying the (semi)automatic analysis of continuous wave (CW) Doppler 
aortic outflow traces and its segmentation, providing a theoretical basis for the 
following clinical applications of this approach.  
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• To define parameters useful in the detection of myocardial (dys-)function in groups of 
patients with ischaemic remodelling and remodelling in valvular heart disease (aortic 
stenosis). In Chapters 4 and 5 the previously described dedicated signal modelling 
algorithm is applied on the LV outflow traces in these patient groups, providing 
specific parameters of myocardial (dys-)function based on the aortic outflow profile 
traces (instantaneous peak velocities).  
 
• To assess the influence of electrical remodelling in patients with left bundle branch 
block on myocardial dysfunction as well as to study acute reverse remodelling in 
these patients immediately after cardiac resynchronization therapy. In Chapter 6, the 
mechanical consequence of the underlying electrical abnormality and its acute 
reversal are studied.  
 
• To examine a group of patients with early acromegalic cardiomyopathy in which 
hypertrophy occurs without significant changes in wall stress. In Chapter 7, 
hypertrophy and hypercontractility in early stage acromegalic cardiomyopathy 
resulting in increased cardiac output and inducing additional signs of vascular 
remodelling are discussed.  
 
• To describe different entities leading to hypertrophic remodelling and define the 
differences in regional deformation based on the various underlying substrates. 
Chapter 8 addresses the changing role of echocardiography in the diagnosis of the 
hypertrophically remodelled myocardium.  
 
 
 
1.4. Hypothesis 
 
The application of different modalities of echocardiographic imaging in various substrates 
of ventricular remodelling enhances the understanding of the underlying pathophysiological 
mechanisms and its relation to global and/or regional functional impairment, thus aiding 
clinical decision making in such patients.   
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Chapter 2 
Velocity and Deformation Imaging for the Assessment of 
Myocardial Dysfunction∗ 
 
 
2.1. Introduction 
Recent developments in echocardiographic imaging technology and processing enabled the 
quantification of myocardial motion and deformation in a clinical setting. Echocardiographic 
strain (-rate) imaging (either based on Doppler Myocardial Imaging (DMI) [1] or speckle 
tracking [2]) provides a relatively easy way to study myocardial deformation. 
It has been shown, both in the early animal lab work based on microcrystal 
measurements, and more recently using the non-invasive image based methodologies, that 
analyzing myocardial velocities and deformation, especially when combined with the 
response to a dobutamine challenge, enables the assessment of myocardial dysfunction in a 
wide range of cardiovascular pathologies (amongst which: coronary artery disease and 
stress echo [3-6]; valvular diseases [7,8]; hypertension [9, 10]; hypertrophic cardiomyopathy 
[11]; cardiac resynchronization therapy [12]; amyloidosis [13]; heart transplantation [14]; 
genetic cardiomyopathies [15, 16]). One of the major strengths of quantitative deformation 
analysis is the discrimination of different ischemic substrates, ranging from acute ischemia, 
over stunning to chronic ischemia with sub-endocardial fibrosis [17].  
For a proper interpretation of velocity and deformation data in a clinical setting, it is 
required to understand cardiac function/mechanics in normality and pathologies, combined 
with knowledge on how intrinsic cardiac function influences motion and deformation.  
 
 
2.2. Assessing Cardiac Function 
For the management of a broad range of heart diseases, a quantitative, reproducible 
approach for the assessment of cardiac (dys-) function is of great importance. However, 
cardiac (dys-) function is a very general and non-specific entity that is defined depending on 
the context. This makes it difficult to unambiguously define, and thus quantify, (dys-) function 
in a clinical context. Intrinsic cardiac function implies the assessment of true contractility of 
the myocardium. Using non-invasive approaches, this is currently not measurable and in 
                                                 
∗ With permission from: Bijnens BH, Cikes M, Claus P, Sutherland GR. Velocity and deformation imaging for the 
assessment of myocardial dysfunction. Eur J Echocardiogr. 2009;10(2):216-26. 
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clinical practice surrogates for true cardiac contractility are assessed and reported as 
reflecting cardiac function.  
Figure 2.1 illustrates how the heart (simplified to the LV) manages to fulfil its task: 
maintaining a constant and adequate blood (volume) flow. The contractile elements of the 
myocardium can develop a contractile force and can shorten. These contractile elements are 
imbedded, with a very specific distribution, in the LV with a certain overall geometry (shape, 
thickness) and with specific elastic properties. By the initial force development of the 
contractile elements, the ventricle can increase its internal pressure up to the point that this is 
high enough to open the aortic valve. From that moment on, the shortening of the contractile 
elements will decrease the cavity size so that its internal blood content is ejected.  
 
Active Force Development
in the myocytes
= intrinsic contractility
Cavity pressure development
Aortic Valve Opening
Ejection by
wall deformation
● Geometry
● Fibre orientation
● Elasticity
● Afterload
 
Figure 2.1: The functioning of the heart. 
 
From Figure 2.1, it is clear that in order to understand the functioning of the heart, all 
aspects, involved in both the development of the internal pressure and the ejection of the 
blood by the reduction (deformation) of the cavity volume, have to be taken into account. Just 
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measuring e.g. the EF, leaves out all information on pressure, tissue properties and the 
transformation from shortening of the individual contractile elements into the global 
deformation of the LV. 
Thus, to fully describe cardiac function, two aspects and their interaction should be 
distinguished: force development (contractility of the myocytes, resulting in the generation of 
sufficient pressure to open the cardiac valves) and deformation (shortening of the myocytes, 
resulting in the actual volume ejection). Additionally, ventricular function can be interpreted 
either from a global perspective as overall pump performance, or from a regional perspective 
where the contributions of individual wall segments are taken into account. The interactions 
between the components force development and deformation are determined by the 
boundary conditions in which the heart functions. 
These include: 
• Wall properties such as tissue composition and elasticity, fiber structure and global 
geometry, which determine the local segment interactions and the resulting wall 
stress 
• Interaction between the heart and peripheral circulation, mostly described as 
(pressure and volume) loading conditions. 
The interpretation of cardiac function data by examining either wall mechanics (regional 
deformation-stress analysis) or pump performance (pressure-volume analysis) requires an 
integration of their measurement in the global picture of the working of the heart (Figure 1). 
In clinical practice, this integration is usually performed in the mind of the investigator and 
only indirect measurements of force development and volume ejection are used to study 
cardiac function. These are mainly based on non-invasive imaging techniques 
(echocardiography, CMR or CT). Usually, patients are followed clinically using 
echocardiography. Two-dimensional and Doppler echocardiography allow both the direct 
anatomical evaluation of the myocardium and the evaluation of haemodynamics. Cardiac 
geometry and the degree of myocardial hypertrophy can be determined by measuring 
ventricular size, wall thickness and myocardial mass index [18].  
For the evaluation of (systolic) cardiac function, the intrinsic properties of the fibres and 
myocytes are the most important, since these determine whether the myocardium is affected 
by the chronic condition and their properties reflect when irreversible damage is induced. 
However, current evaluation is based on global indices such as ejection fraction and 
fractional shortening. These volume based parameters have important limitations in reflecting 
contractility in the context of abnormal loading conditions because: 
• The assessment of intrinsic function based on volume parameters, like fractional 
shortening and ejection fraction, depends on geometric assumptions. It is not well 
understood how these are influenced by wall thickness or ventricular shape. Often 
 15
'supra-normal' values of EF are measured in hypertrophied or volume overloaded 
ventricles. It is unclear whether these really reflect actual changes in contractility [7]. 
• All volume based indices are load-dependent. During disease progression, changes 
in loading or geometry will affect functional evaluation. For the serial assessment of 
myocardial contractility in such patients, an integrated approach, which takes into 
consideration geometry and loading, is required. 
• Conventional parameters only assess global function. In most conditions, which show 
alterations in myocardial contractility, the assessment of regional ventricular function 
is important. Additionally, several of the methods for global assessment concentrate 
only on radial function, ignoring longitudinal function, which in most cardiac pathology 
is altered before changes occur in radial indices [19]. Increased radial function often 
acts as a compensation for the reduction in global longitudinal function.  
• Global measurements do not take into account segment interactions that e.g. only 
result in local wall deformation which does not contribute to pressure build up or a 
reduction in global ventricular volume [20]. 
To overcome some of these concerns, new echocardiographic methods have been 
proposed to assess regional ventricular function based on myocardial motion and 
deformation. One of these, which has proven to be both important for understanding cardiac 
physiology and of clinical value is Tissue Doppler imaging, which allows the quantification of 
myocardial velocities [1]. Post processing techniques, based on acquired velocity data, allow 
the calculation of regional myocardial deformation (strain rate or rate of deformation and 
strain or amount of deformation) while post processing of grayscale images (using speckle 
tracking or registration techniques) can provide information on displacement and 
deformation. In a lot of cardiac pathologies, the reduction in myocardial deformation 
correlates well with the severity of the disease [21, 22]. However, it is yet unclear whether 
this is entirely due to a decrease in function or rather related to changes in cardiac geometry 
and loading.  
 
 
2.3. Myocardial Motion and Deformation 
Using either Doppler Myocardial Imaging (also referred to as Tissue Doppler Imaging or 
Myocardial Velocity Imaging) or grayscale speckle tracking, motion of myocardial segments 
can be recorded and quantified.  
Figure 2.2A shows the motion components that can be assessed based on 
echocardiographic imaging. From an apical view, the longitudinal motion (the base of the LV 
moving towards the (normally) fixed apex) can be assessed while from using a parasternal 
(short or long-axis) view, the inward radial motion can be measured. 
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Either by calculating the spatial gradients of the obtained myocardial velocities [1] or by 
using a grayscale imaging approach (speckle tracking) [23], local myocardial deformation 
can be quantified. In reality, the deformation of a myocardial segment during the cardiac 
cycle is very complex [24] (Fig 2.2B) and contains both normal deformation (longitudinal 
shortening/lengthening, radial thickening/thinning and circumferential shortening/lengthening) 
and shear (base-apex twisting, epi-endo circumferential shear and epi-endo longitudinal 
shear) [1, 25, 26].  
Figure 2.2C shows a typical longitudinal velocity and displacement (the temporal integral 
of the velocity) from a normal individual (using high frame-rate DMI). Figure 2.2D represents 
the corresponding deformation (strain) and speed of deformation (strain-rate). Note that there 
is a clear gradient from base to apex in both velocity and displacement, which corresponds to 
the stationarity of the apex within the thorax while the base moves towards it. In contrast, 
deformation is more or less homogenous throughout the (normal) myocardial wall. These 
patterns will be altered in cardiac pathologies (see further). Using Doppler based 
approaches, mainly longitudinal and radial motion/deformation is studied, since it is difficult to 
align the circumferential motion with the ultrasound beam, as is required with this technique. 
With speckle tracking, longitudinal and circumferential motion/deformation is most commonly 
analyzed, since the intrinsic spatial resolution of the images is limited, making it difficult to 
track the tissue within the (thin) wall. Moreover, the lateral resolution of ultrasound images is 
intrinsically less than in the axial direction, making it more difficult to assess radial 
deformation from an apical view [27, 28]. Additionally, speckle tracking allows the 
assessment of cardiac rotation and torsion (if measured at different levels) [29]. When using 
either of the approaches, it is important to note the inherent differences in the results. DMI 
works at higher temporal resolution (>150 Hz), making that it is more suited to assess that 
fast events, as are observed in velocities and strain-rates (especially in the iso-volumic 
periods), while for the quantification of displacements and strain, the inherent lower frame-
rate used for speckle tracking (<90Hz) would be sufficient. Speckle tracking has shown to be 
more reproducible and requires less user expertise, but inherently uses more spatial and 
temporal averaging of the obtained profiles, resulting in significantly lower values when 
compared to DMI and a decreased ability in detecting smaller abnormal regions [27, 28, 30, 
31]. 
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Figure 2.2: Myocardial motion and deformation consists of 3 major components: 
longitudinal, radial and circumferential (A, B). The total deformation, from end-diastole to 
end-systole, of a myocardial segment is very complex and includes shortening, thickening 
and shearing (B). Typical profiles for the velocity, displacement (C) and strain-rate, strain (D) 
traces during one cardiac cycle in normal myocardium.  
 
 
2.4. The Relation between Myocardial Function (Contractility) and Regional 
Deformation 
When using myocardial motion or deformation to assess (dys-) function, it is important to 
understand the relation between intrinsic function (contractility) and the resulting 
motion/deformation. 
In general, the relation between the forces acting up on an object and the resulting 
deformation of that object is described by Hooke's law. This law states that forces (mostly 
expressed as stress and with units pascal (Pa)) and deformation (mostly Lagrangian 
(relative) deformation and expressed as a percentage) are linked by the elasticity (with units 
Pa) of the object. The more elastic an object, the more it will be deformed by a certain force. 
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This relation (which is also time-variant), when applied to myocardium, is illustrated in Figure 
2.3. 
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Figure 2.3: The relationship between local forces and deformation. 
 
In a myocardial segment, both the force developed by the segment, as well as all forces 
developed on the segment have to be taken into account. Obviously, the internal contractile 
force (the intrinsic contractility of the myocardium, a force trying to shorten the myocytes, 
thus resulting in negative deformation) is the most important. However, it has to be kept in 
mind that any piece of myocardium is always imbedded in a ventricle, resulting in external 
forces acting up on it (and mostly working in the opposite direction of the contractile force). 
These forces are described as the loading of the tissue and consist of the local wall stress, 
caused by the intra-cavity pressure (whose influence is related to local geometry of the 
ventricle), and the interaction with neighboring, contracting, segments (each contracting 
neighboring segment will pull the segment under investigation). 
As for any object, the relation between all acting forces and the resultant deformation is 
ruled by the regional elasticity, which, for myocardium, translates in the fiber/matrix structure 
and the presence or absence of fibrosis and depositions. Also, it must be kept in mind that 
elasticity is not a constant, since, due to the matrix structure of the tissue, the more 
myocardium is stretched, the more difficult it becomes to stretch it even further. 
In summary, the main factors influencing regional myocardial deformation are (Figure 2.4): 
• Intrinsic contractility i.e. the contractile force developed by the myocardium 
(influenced by tissue perfusion and electrical activation and being developed in 
the early part of the ejection phase, peaking around one third of it) [32]. 
• Cavity pressure (often referred to as afterload and influenced by preload), whose 
influence is related to the local ventricular geometry [33]. 
• Segment interaction (the influence of the contracting neighbouring segment) [20]. 
• Tissue elasticity (which is dependent on the local histology (fibrosis) and on the 
amount that the myocardium is already stretched) [34]. 
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Thus, these influencing factors consist of one active force (contractility), two passive 
forces (pressure and segment interaction) and the tissue properties. This is graphically 
presented in Figure 2.4, which shows a schematic short-axis cross section of the left 
ventricle.  
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Figure 2.4: The local forces acting upon a myocardial segment. 
 
 
 
 
 
 
 
 
 
 
 
 20
2.5. Clinical Application 
2.5.1. Coronary Artery Disease 
Coronary artery disease and the underlying ischemic substrates have been studied 
extensively using velocities and deformation (both based on invasive ultrasound crystal 
measurement and non-invasive imaging (echocardiography and magnetic resonance 
imaging)) [21, 35-37]. It was shown that myocardial motion and deformation react very 
predictably on changes in regional perfusion of the presence of infarction [17]. 
In summary, regional velocities as well as peak systolic strain-rate and end-systolic strain 
reduce linearly with a reduction in regional perfusion or the presence of sub-endocardial 
fibrosis. Simultaneously, post-systolic motion/deformation is developing. When challenged 
with dobutamine, acutely ischemic tissue will show even less deformation, while post-systolic 
deformation is increased, whereas normal tissue shows increased deformation (continuously 
increasing strain-rate and increasing strain as long as filling is not reduced by increased 
heart-rate). In contrast, partial thickness chronic infarction will show a very moderate 
deformation increase (depending on the transmurality) when stimulated with dobutamine. 
Interestingly, while stunned myocardium shows decreased deformation at rest, associated 
with post-systolic deformation, when stimulated with dobutamine, systolic deformation almost 
restores to normal and post-systolic deformation almost completely disappears [17]. This 
behavior of stunned myocardium can be attributed to myofibrillar oedema, increasing the 
spacing within the contractile elements of the myocardium and thus reducing the effective 
force it can develop [38]. 
Additionally, it was shown that full pressure reperfusion of an acute infarct influences 
deformation. If reperfusion is within a short period of time after the onset of symptoms, the 
myocardial deformation will normalize quickly (potentially after some period of stunning). 
However, when reperfusion is within a time-span of about 1.5 to 6 hours, interstitial 
myocardial oedema will develop, resulting in a sudden increase in end-diastolic wall 
thickness of the infarcted segment at the moment of reperfusion. This is associated with the 
total absence of regional deformation [39, 40]. With reperfusion later than about 6 hours after 
onset of symptoms, the myocardial wall has thinned and does not deform and reperfusion 
does not alter this significantly. 
Thus, deformation analysis at baseline and its response to a dobutamine challenge 
enables to uniquely distinguish the different ischemic substrates (Figure 2.5). 
This makes the combination of the measurement of baseline deformation (in a lesser 
extent: motion), combined with the response to a dobutamine stress echo, a potent clinical 
tool for the assessment of the ischemic substrate in a clinical patient. 
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Figure 2.5: An overview of the regional deformation and wall thickness of the different 
ischaemic substrates at rest and how they respond to dobutamine. From [1], with permission. 
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2.5.2. Volume Overload 
As discussed above, deformation is also related to ventricular geometry. Dilatation is an 
adaptive mechanism used by the ventricle to cope with the problem of generating sufficient 
cardiac output to fulfil the needs of the body. There is a clear relationship between ventricular 
size and the generated stroke volume for a certain available contractile force. An enlarged 
ventricle can more easily generate a larger stroke volume than a smaller one. This can be 
easily understood since in a spherical or ellipsoid object, the volume of the outermost part is 
always larger than the volume of the innermost part, which means that similar deformation 
(determined by the contractile force) can generate a larger stroke volume in a dilated heart. 
Similarly, the same amount of stroke volume can be generated with less contractility in a 
dilated heart. Thus, as the ventricle dilates, with a preservation of stroke volume, regional 
deformation reduces without any change in contractility. However, when stroke volume 
increases (as in valve regurgitation), myocardial deformation can increase. In these cases, 
only when contractility additionally reduces, there is a marked decrease in deformation [7]. 
Normalising deformation with ventricular volume might be a useful approach to isolate the 
effect of geometry and changing contractility in volume overloaded ventricle [7]. 
 
2.5.3. Pressure Overload 
Several cardiac conditions are associated with progressive remodelling of the ventricle. 
Examples of this include pressure or volume overload due to valvular stenosis or 
regurgitation, coronary artery disease with associated decreased contractility and fibrosis 
leading to ventricular dilatation, genetic abnormalities resulting in hypertrophy and 
progressive development of local fibrosis, severe hypertension, conduction abnormalities, 
etc. 
Remodelling is in the first instance a response to a problem with either the muscle itself or 
the environment in which it has to work and is an attempt to keep on fulfilling the heart's task 
- circulating the blood. However, since this is an abnormal situation with inherent mechanical 
disadvantages, in the long term, this will lead to irreversible damage to the muscle which 
evolves into ventricular dysfunction and heart failure. The early detection and follow-up of 
changes in cardiac function and myocardial properties is thus of major importance.  
Myocardial velocities and deformation have proven useful in several conditions with 
altered myocardial properties or geometry. 
With pressure overload pathology, the basal septal segment is the first to show changes 
(figure 6). Both a decrease in strain (-rate) and the development of post-systolic 
motion/deformation is observed, as well as the development of localized hypertrophy [9]. 
With increasing overload the whole ventricle becomes hypertrophic and deforms less. The 
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development of regional fibrosis further diminishes deformation. Thus, basal septal 
deformation is the most sensitive to changes in pressure overload pathology. 
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Figure 2.6: Hypertension results in ventricular remodelling, with the initial development of 
basal septal hypertrophy (septal bulge) due to increased wall stress associated with the 
bigger local radius of curvature. This is associated with reduced systolic deformation and the 
development of post-systolic deformation. 
 
2.5.4. Genetic Cardiomyopathies 
Hypertrophic cardiomyopathy is associated with the presence of regional abnormalities in 
myocardial fibre arrangement, resulting in local dysfunctional myocardium. Using regional 
deformation analysis, these areas of histological abnormalities can be easily localized since 
they do not show any systolic deformation, while the rest of the (hypertrophic) segments still 
deform (although mostly much reduced compared to normal).  
 
In genetic diseases such as Friedreich's Ataxia, Fabry Disease or Duchenne 
Cardiomyopathy, regional deformation is first changing in the infero-lateral segment. As 
fibrosis develops first in this area, local strain-rates reduce and post-systolic deformation 
becomes apparent. This knowledge can be used to assess the efficacy of novel (very 
expensive) medical therapies [15]. 
 
2.5.5. Left Bundle Branch Block and Cardiac Resynchronization Therapy 
The availability of cardiac resynchronization therapy (CRT) has drastically changed the 
management of heart failure patients with dilated cardiomyopathies and left bundle branch 
block. In these patients, it is assumed that the abnormal conduction leads to a late activation 
of the lateral wall, resulting in an important reduction in cardiac function. Although about 70% 
of these patients clearly benefit from biventricular pacing, there is still a lot of debate about 
the best method to assess those patients that will most benefit from the treatment [41, 42].  
 24
The current approach to select potential responders is to get a more direct evaluation of 
late contractility by (echocardiographically) searching for the presence of mechanical 
dyssynchrony and trying to identify a severely delayed wall with potentially recruitable 
function, rather than looking only for ECG manifestations of ventricular conduction delay 
which poorly correlate with the actual ventricular mechanical events. Many methods have 
been proposed to quantify dyssynchrony. These can be classified as evaluating either the 
Inter-ventricular delay (assessing the time difference between right and left ventricular 
contraction) or the Intra-ventricular delay (looking at timing of the motion/deformation of 
opposite ventricular walls).  
To assess intra-ventricular delays, both M-mode (measuring the time difference between 
maximal septal and posterior excursion) and velocity/deformation based methods have been 
proposed.  
Velocity and deformation based methods mostly assess the time differences between 
maximal values from different myocardial segments. However, most methods are based on 
longitudinal motion. Patients eligible for CRT mostly have dilated ventricles with complex 
motion (including rocking) and low velocities. Especially the additional presence of infarcted 
areas makes the interpretation of the (longitudinal) velocity traces very challenging. Because 
local myocardial motion reflects both contractile function and the influence of other 
myocardial segments (tethering), using local velocities to extract information on timing of 
contraction is almost impossible. Especially in dilated hearts, with poor LV function, local 
motion can be importantly influenced, even by right ventricular motion [43]. This makes that 
most imaging parameters have proven to be not ideal to assess potential response to CRT 
[44]. 
A more appropriate approach to assess these patients is searching for the underlying 
pathophysiological aethiology of their heart failure [1]. Besides problems with diastolic filling 
resulting from inappropriate atrio-ventricular delays, in a subgroup of patients there are 
typical and specific signs of LBBB and associated changes in cardiac mechanics. 
'True' mechanical dyssynchrony originates from a delayed electrical activation of one of 
the myocardial walls.  In a normal left ventricle, all segments are activated almost 
simultaneously and are thus deforming (longitudinal shortening and radial thickening) at the 
same time (Figure 2.7A). While the septum starts contracting, it contributes to pressure build 
up and ejection, but at the same time, it also pulls the lateral wall towards it. Similarly, the 
lateral wall will contribute to the pressure build up and ejection and will pull the septum 
towards it with an equal strength. The result is that both the septal and lateral annuli are 
dragged towards the apex, which remains stationary. 
However, if there is a significant delay in the activation (and thus onset of contraction) of 
the lateral wall, the interaction between the walls changes significantly. When the septum is 
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activated, there is a period where it is actively developing a contractile force and shortening 
while the contralateral wall is not. This means that it exerts a pulling effect on the latent 
opposite wall which is not counterbalanced by contraction of the latter. Because it now 
contracts against a reduced load, it will move/shorten faster than it would in a normal 
ventricle (Figure 2.7B). Additionally, this will result in an early stretching of the, still relaxed, 
lateral wall.  As soon as the lateral wall is electrically activated, it starts to contract and thus 
will start in its turn to influence the septum. The pulling force from the (later activated) 
contracting lateral wall will stretch the septum.  
This sequence of motion and deformation in septal and lateral wall can be easily 
appreciated from the regional motion and deformation traces. Figure 2.7C shows the (radial) 
velocities of the septal and infero-lateral wall of a normal individual and a patient with LBBB. 
While normally, the septal and infero-lateral wall show similar, but mirrored velocity (both 
moving inward, thus with opposite directions with regard to the transducer), in LBBB  the 
septum shows a very large inward velocity as soon as it is activated, almost immediately 
followed by a fast outward motion when the infero-lateral wall is starting to contract. This can 
also be appreciated from slowed-down grayscale images, where the septum rapidly moves in 
and outward, resulting in a ‘septal flash’ motion. This ‘septal flash’ is not only fast septal 
motion, but is a result of fast septal deformation (Fig 2.7D, E, F) where there is rapid 
thickening of the septum (while the lateral wall is stretched) followed by thinning when the 
lateral wall contracts and thickens. 
 The combination of the unloaded contraction of the septum stretching the lateral wall 
followed by the late lateral wall contraction stretching the septum will result in very inefficient 
global contraction, in which a lot of energy and force is wasted in deforming opposing 
myocardium without contributing to ejection. This will ultimately lead to symptomatic heart 
failure. Correcting the difference in local activation and deformation using CRT will result in a 
marked improvement in cardiac function and reverse geometrical remodelling in patients 
showing these specific mechanical signs of LBBB. 
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Figure 2.7: Myocardial velocities and deformation in patients with LBBB, compared to normal 
individuals. 
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2.5.6. Diastolic Function 
Myocardial velocities have been suggested to be useful to assess diastolic function. 
Especially the ratio of early mitral flow velocities (E) and early basal myocardial velocities (E’) 
was shown to correlate with relaxation abnormalities [45] and filling pressures [46]. 
However, in order to understand its use and recognize the pitfalls of this approach, it is 
important to keep in mind what these velocities represent. When assessing diastolic function, 
one wants to get an idea on how much (volume) filling is happening in the early relaxation 
phase (related to ventricular compliance and intrinsic myocyte relaxation) and at which 
pressures (elevated end-diastolic and atrial pressure) this is taking place. When quantifying 
mitral blood flow velocities, one assesses the pressure gradient, between the atrium and the 
ventricle, driving the flow (figure 2.8, left). This means that a high E can reflect as well 
(normal) low LV pressure with normal LA pressure, as well as elevated LA pressures 
(pseudo-normalization). When measuring basal myocardial velocities or ring motion, one 
assesses the dynamics of the basal LV displacement, which can be seen as a surrogate of 
global LV volume change (global LV deformation) (figure 2.8, right). Thus, E’ provides 
information on how much volume is entering the LV in the early filling period. This makes that 
the ratio E/E’ provides information on how much volume enters the ventricle for a given LA-
LV pressure gradient. This means that in all situations where E’ does not properly reflect 
global LV volume changes (large infarctions, LV dilatation, LBBB, primary mitral 
regurgitation, hypertrophy, etc.), the ratio E/E’ is not reflecting diastolic function and should 
be used with caution [47, 48]. 
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Figure 2.8: Myocardial velocities and deformation in patients with LBBB, compared to 
normal individuals. 
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2.6. Conclusion 
Regional myocardial velocities and deformation prove to be a powerful tool to understand 
and quantify myocardial (dys-) function. Several cardiac conditions are associated with very 
specific changes in motion and deformation, which can be quantified using 
echocardiographic techniques. Analyzing myocardial deformation has provided important 
insights in cardiac mechanics and in the understanding of changes induced by a range of 
cardiac pathologies. Although none of the current techniques for ultrasound deformation 
assessment is perfect (DMI-strain has a steep learning curve and is very sensitive to the 
acquisition while speckle tracking strain works with low temporal resolution and important 
spatial and temporal smoothing), they still provide insight for the assessment of cardiac 
function in individual patients. Although the relation between local myocardial contractility 
and regional deformation is complex and dependent on loading and geometry, it was shown 
that the deformation assessment (potentially combined with dobutamine stimulation) 
provides useful additional information, especially for the clinical assessment of coronary 
artery disease and hypertrophic hearts. 
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Chapter 3 
Analysis of Doppler Ultrasound Outflow Profiles for the Detection 
of Changes in Cardiac Function∗ 
 
 
 
3.1. Introduction 
The detection of changes in myocardial contractility in the setting of coronary artery disease 
is a very important medical task. Besides a decrease in global systolic function, as detected 
by ejection fraction, and changes in regional deformation [1], it was suggested, from isolated 
myocytes research, that chronic ischemia decreases but prolongs contraction [49]. 
Ultrasonic imaging is a non-invasive medical imaging modality, which is routinely used in 
hospitals for the examination of cardiac patients. Doppler ultrasound imaging provides useful 
information about blood velocities through the cardiac valves [50]. From these, clinical 
information on LV inflow (mitral valve) and outflow (aortic valve) are obtained, which may be 
important for diagnosis. In current practice, CW Doppler outflow traces are mainly used to 
assess a potential pressure gradient across the aortic valve resulting from a narrowing of the 
valve. It was also shown that severe aortic stenosis shows not only higher but often also 
prolonged outflow velocities [51]. 
From these observations, we hypothesize that the profile of the aortic outflow velocities 
might provide information on global myocardial function [52]. Outflow velocities represent the 
pressure gradient between LV and aorta and are thus influenced by either of them. A 
dynamically increasing resistance in the vessel tree, as could be expected in the presence of 
pathology, reduces late velocities while a prolonged development of contractile force by the 
myocardium should show as an increase in late velocities. Thus, we assume a relationship 
between the morphology and duration of aortic outflow velocities and myocardial function. 
To study this relation and its usefulness to provide diagnostic clinical information, we 
propose a novel method for Doppler signal analysis. To test the hypothesis, various features 
of the envelope of the aortic outflow were extracted. To study the potential of these features 
to discriminate normal cardiac function from changes induced by coronary artery disease, 
ROC curves have been calculated and the area under the ROC curves was used to obtain a 
quantitative measure of feature performance. 
 
                                                 
∗ With permission from: Kalinic H, Loncaric S, Cikes M, Baltabaeva A, Parsai C, Separovic J, Cikes I, Sutherland 
GR and Bijnens B. Analysis of Doppler Ultrasound Outflow Profiles for the Detection of changes in Cardiac 
Function. In International Symposium on Image and Signal Processing and Analysis (ISPA), 2007, 326-331. 
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3.2. Method for ultrasound signal analysis 
The proposed method for analysis of Doppler ultrasound signals consists of several steps. In 
the first step, an image acquired from the ultrasound scanner is automatically converted into 
a 1-D aortic outflow velocity signal.  In the second step, manual signal segmentation of the 
time interval of interest of the 1-D velocity signal is performed by an expert cardiologist. In 
the third step, signal modelling is done in order to eliminate noise. In the final step, signal 
feature extraction is performed to enable quantification of the signal to analyse and compare 
signals from normal individuals and patients with ongoing coronary artery disease. The 
block-diagram of the proposed method is shown in Figure 3.1. Details are described in 
Sections 3.3-3.5. Experimental results are presented in Section 3.6. 
 
 
3.3. Signal extraction 
Continuous wave Doppler traces of the aortic outflow were acquired with a clinical echo-
cardiographic scanner (Vivid 7, GE Healthcare) using an apical 5-chamber view. Images 
were digitally stored in 'raw' Dicom format, containing the spectral Doppler information in 
proprietary tags. These 'raw' Dicom images were converted into Hierarchical Data Format 
(HDF) using an Echopac workstation (GE Healthcare).  
The image (Figure 3.2), containing information about aortic flow, was extracted from the 
input HDF file. In the obtained image, the intensities represent the Doppler shift of the beam, 
or the velocities of the objects in the direction of the scan line. The signal extraction from the 
image is divided in automated and manual steps. In the automated step of the procedure, the 
envelope of the Doppler ultrasound signal is detected. In the manual step, the expert 
selected the relevant portion of the blood flow trace. 
 
 
Figure 3.1: The block diagram of the proposed method for signal extraction 
 
3.3.1. Automated extraction 
The CW Doppler signal (Figure 3.2.) represents the time-change of velocities along a scan 
line in the 2-D ultrasound imaging plane. In this study, we are interested in the velocities in 
the narrowest part of the outflow (the atrium-ventricular connection). Thus, the relevant 
information is the instantaneous maximal velocity (i.e. the envelope) of the CW Doppler 
traces. Since the upper part of the Doppler signal (Figure 3.2.) represents negative velocities 
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and contains no relevant information for this study, the first problem was to detect the zero-
level of the signal, and eliminate the irrelevant part. To detect the zero-level, the image was 
projected onto the y-axis. On the projection (Figure 3.3, left) the zero-level is recognized as 
the minimum between two peaks. To detect that minimum correctly, we performed a cross-
correlation of the projection with a negative sine. The sine’s width is defined by the number of 
dark pixels on the upper part of the image where the zero-level is expected. Figure 3.3, right, 
shows the result of the cross-correlation. 
 
Figure 3.2: Image extracted out of HDF 
 
Figure 3.3: Results of y-axis projection and crosscorrelation 
 
After the negative part of the signal is discarded, the procedure focuses on envelope 
detection. Figure 3.4. shows the Doppler trace together with the extracted envelope (left) and 
the resulting signal, corresponding to the instantaneous maximal velocity (right). 
 
 
Figure 3.4.: Doppler trace and its envelope 
 
3.3.2. Manual control and timing of the cycle 
In the following step of the procedure, a cardiologist reviewed the result of the automated 
signal extraction and discarded the signals that could not be analysed due to excessive noise 
 32
or incorrect signal extraction. For the accepted cases, the region of interest (i.e. the ejection 
time) of the signal was manually defined by the cardiologist by indicating aortic valve opening 
and closure. To ease this work, an application was created that helped cardiologist to select 
the acceptable images and to mark aortic valve opening and closure. The graphical user 
interface of this application is shown in Figure 3.5, where two regions of interest are indicated 
by vertical lines. Figure 3.6. shows the resulting signal. 
 
 
 
Figure 3.5: GUI of the application used for the manual 
control and timing of the cycle 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: Region of interest 
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3.4. Signal modelling (interpolation) 
The signal obtained in the previous step is usually very noisy and regularly contains 
artefacts, mainly corresponding to the ‘valve clicks’ (the broadband Doppler signal generated 
by the opening and closure of the aortic valve). These artefacts should be removed as they 
could interfere with the feature extraction in the next processing step. Since the noise on the 
signal is non-physiologically (the hart cannot produce high frequencies), it should be 
removed. We investigated two different approaches for eliminating signal noise. In the first 
approach, the noisy signal is filtered in the Fourier domain to remove the high frequencies 
that the human hart cannot produce. In the second approach, a polynomial approximation of 
the original noisy signal was used to obtain a smooth representation. In the assumption that 
the velocity is proportional to the remaining volume and the cardiac length is decreasing 
linearly, velocities would change with a third power. Following this idea we approximated the 
signal with two piecewise cubic polynomials.  
Using both approaches, the noise was eliminated and the glitches at the beginning and the 
end of the signal were smoothed. 
 
 
3.5. Signal feature extraction 
From the signals, 14 features describing their shape were extracted, namely, peak value, 
time to peak, rise time, fall time, signal width at 10%, 50% and 90% of the peak, first 
harmonic, second harmonic, even harmonics, odd harmonics, an asymmetry factor, area 
under the curve and signal length. Rise and fall times are defined from 10% to 90% of the 
peak as illustrated in Figure 3.7. The asymmetry measure was defined as the difference 
between the areas of the right and left half (in the temporal dimension) of the signal. Out of 
these basic 14 features we derived 17 additional features by normalisation or combing two 
basic features. 
 
 
 
 
 
 
 
 
 
 
Figure 3.7: Signal rise and fall time 
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The feature set was selected based on the problem domain and the physical meaning of 
each attribute. The hypothesis is that some of these features are relevant for detecting 
changes in cardiac function so that their distributions could differ for normal individuals and 
abnormal patients. To detect the most useful features for diagnosis, we have calculated their 
ROC curves. The area under the ROC curve was used as a measure for the diagnostic 
potential of each feature. 
 
 
3.6. Experimental results 
In this study, we included 88 patients scheduled for a routine dobutamine stress echo study. 
Of these, 38/88 had signs of ongoing coronary artery disease at baseline, 40/88 showed 
normal cardiac function at baseline but had a positive response to the stress test and 10/88 
showed no signs of ongoing coronary artery disease (normal contraction both at baseline 
and during the stress test). Additionally, 24 normal volunteers, with no evidence of coronary 
artery disease on clinical and echocardiographic examination, were included. For all these 
individuals, the CW Doppler traces of the aortic flow (at baseline) were acquired and 
analysed.  
 
3.6.1. Signal extraction 
For signal extraction we used the method described in Section 3. The Doppler images were 
first filtered using a Gaussian for noise reduction. Since blurring the image too much could 
cause loss of information, we choose to use a 3x3 Gaussian filter with σ = 0.5. After this, the 
zero-level was determined by cross-correlation, as described in Section 3.2. Since the 
negative part of a sine wave (which is real and symmetric) was used for this, convolution 
could be used instead of cross-correlation. After zero-level detection the irrelevant part was 
discarded and the image was smoothed once again. In the next step, a segmentation 
threshold was chosen defined by the mean value of the image increased by a parameter p. 
The value of p was experimentally determined, and, in our case, p=20 was chosen. In the 
resulting binary image, the edge was detected as the top-most pixel in the image with an 
intensity that corresponds to the signal. The procedure is shown in three steps in Figure 3.8. 
 
       Image             No-zero image             Envelope 
 
Figure 3.7: Three steps of automatic signal extraction 
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The signal quality was checked and the region of interest was indicated by a cardiologist, 
as described in Section 3.3 (Figure 3.5).  
 
3.6.2. Signal modelling 
Two approaches to signal conditioning were implemented. In the first approach, conventional 
filtering in the Fourier domain was used. Before the Fourier transform was calculated, the 
signal was anti-symmetrically extended (Figure 3.9). In this way, the harmonics of the Fourier 
transform corresponded to the harmonics of the extended signal. The signal conditioning was 
performed by filtering out all harmonics except the first ten. The filtered signal, overlaying its 
original, is shown in Figure 3.9. 
 
Figure 3.8: The asymmetrically extended original signal and overlaying filtered signal  
 
In the second approach, a piecewise cubic polynomial approximation was used. Four fixed 
points were chosen for polynomial signal approximation: beginning, end, maximum and half 
way between the maximum and the end of the signal. These points were picked as fixed 
points for signal approximation (Equations (1) – (5)). With these points, the signal was 
divided in two portions joining at the signal maximum. The first portion was approximated 
with a cubic polynomial (Equation (9)) and the second portion with another cubic polynomial 
(Equation (10)). To achieve a smooth approximation, the first derivatives of both cubic 
polynomials at the maximum of the signal are forced to zero (Equations (6), (7)) and their 
second derivatives to be equal in that point (Equation 8). In this way we obtained a system of 
eight linear equations with eight unknowns. An example of a signal created using this 
approximation is shown in Figure 3.10, overlaying the original signal. 
 
The system has been solved as shown below. The equations used in the cubic 
approximations were: 
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where f1 and f2 are: 
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which, after a rewrite in matrix form leads to: 
 
X*A=Y,    (11) 
 
where A is an unknown column vector, X an 8x8 matrix, and Y the vector containing the 
values of the function and its derivatives. 
 
A = X-1*Y    (12) 
 
The parameters of the cubic equations were calculated as shown in (Equation 12). The 
original signal and its approximation are shown in Figure 3.10. 
 
 
Figure 3.9: The original signal and its piecewise cubic approximation. 
 
3.6.3. Signal interpretation 
The smoothed signal approximation, obtained in the previous step, was used for feature 
extraction. The feature extraction procedure was applied to three different versions of the 
signal: i) the original signal, ii) the first ten harmonics of the Fourier transform, and iii) the 
piecewise cubic approximation of the signal. The features that were extracted are listed in 
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Table 3.1. An ROC analysis was performed for each feature to describe its performance to 
detect patients with signs of ongoing coronary artery disease (baseline abnormalities or a 
positive response to dobutamine stress). Table 3.1. lists the corresponding areas under the 
ROC curves for the features extracted from three different signal versions. 
When studying the features, one can notice a significant difference between their 
distributions for normal individuals and patients. Figure 3.11. shows the histogram for the fall 
time, showing the difference between the mean values for normals and patients. This 
difference is quantified by the ROC curve of this feature. Picking a threshold and shifting it 
through the different values of the given feature results in different numbers of true positives 
and false positives. Sliding this threshold over the range of values, results in the ROC curve. 
The difference of change (derivate) between true positives and false positives describes how 
different the histograms of normals and patients are (at the given threshold). This can be 
quantified in the value of the area under ROC curve. The greater the area under ROC curve, 
the greater the capability for detecting more true positives with less true negatives, therefore 
the distance between the mean values of normals and patients is greater. This property was 
used as a measure of how much information about disease is present in each feature, or, in 
other words, how different normals and patients are with respect to this feature. The example 
of the ROC curve for the fall time is given in Figure 3.11. (right). 
 
 
Figure 3.10: Histogram and ROC curve for fall time extracted out of original signal 
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Feature Original 
signal 
Fourier 
filtered 
Cubic 
approximated 
max 0,63108 0,66059 0,63021 
tmax 0,57509 0,50391 0,53819 
T_rise 0,6059 0,50521 0,53082 
w10 0,57813 0,52604 0,53299 
w50 0,53212 0,50347 0,5026 
w90 0,5803 0,59983 0,50217 
T_fall 0,59071 0,55859 0,55252 
h1 0,61979 0,61979 0,64714 
h2 0,59071 0,59071 0,625 
hodd 0,61502 0,57726 0,53385 
heven 0,51866 0,5612 0,55425 
asymm 0,60981 0,58594 0,61589 
A 0,63585 0,6428 0,65234 
T 0,55295 0,55295 0,55295 
max/T 0,64366 0,65451 0,64583 
tmax/T 0,61979 0,52517 0,54253 
Tmax/max 0,50087 0,58811 0,61979 
t_rise/T 0,60286 0,50477 0,55469 
T_rise/max 0,53776 0,55859 0,61979 
W10/T 0,52734 0,58464 0,60851 
W10/max 0,58854 0,61892 0,63064 
W50/T 0,51042 0,56163 0,57986 
W50/max 0,65061 0,60807 0,58984 
W90/T 0,57856 0,61285 0,6033 
W90/max 0,6046 0,55599 0,64366 
T_fall/T 0,59071 0,60113 0,5842 
T_fall/max 0,51953 0,51866 0,51215 
h1/h2 0,5803 0,5803 0,54905 
hodd/heven 0,59939 0,50825 0,52691 
asymm/A 0,5803 0,55642 0,57161 
A/max 0,53385 0,53168 0,51519 
 
Table 3.1: Areas under ROC curves for extracted features 
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From Table 3.1. and the areas under the ROC curves, we can conclude that features 
describing the signal’s symmetry or morphology contain information about disease. This 
includes features such as t_fall, t_max/T, asymm, t_fall/T, t_rise/T. Thus, this approach could 
be used to classify aortic flow patterns in being normal or abnormal, based on one individual 
feature or a combination of features, using a higher dimensional approach. 
Figure 3.12. shows the scatter plot of 2 features related to the signal’s morphology (fall 
time and asymmetry). It can be observed that the normal individuals cluster in the top right 
corner while in the group of patients with signs of  ongoing coronary artery disease, there is a 
clear subgroup with a different aortic flow profile (more symmetric and overall broader). In 
figure 3.13, the patients scheduled for a stress test, but with a normal response to it, are 
plotted, together with an indication of the normal range that could be expected for this feature 
(mean ± 2 SD). It is clear that within these patients with apparently normal cardiac function, 
there is a subgroup which shows clearly altered aortic flow profiles, suggesting the presence 
of sub-clinical changes.  
 
 
 
Figure 3.11: Patients (star) and normals (circle) distribution in  
fall time – asymmetry feature space 
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Figure 3.12: Distribution of patients with a normal response to stress 
 
 
3.7. Conclusion 
In this paper we presented a novel method for the analysis of aortic outflow velocity signals 
obtained from echocardiographic CW Doppler imaging. The extracted velocity profiles were 
modelled using two different approaches. Feature extraction was done on the original signal 
as well as on the two modelled versions. For each feature, the area under the ROC curve 
has been calculated to describe its ability to discriminate normal individuals from patients 
with signs of ongoing coronary artery disease. Thirty one different features were investigated.  
The experimental results showed that all three signal representations yielded 
approximately the same quality of discrimination and the results provided a better insight 
regarding the choice of the best feature.  
The signal analysis has shown that the probabilistic distributions of the various features 
are different for normals and patients. This shows its potential for diagnostic use in the 
presence of coronary artery disease 
The features discriminating the best between normals and patients were related to the 
signal morphology with a wider signal in patients. This suggests that the broadening of the 
aortic valve profile contains information on changes in cardiac function in the presence of 
coronary artery disease and thus might be used as an additional diagnostic tool in clinical 
practice. 
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Chapter 4 
The Shape of the Aortic Outflow Velocity Profile Revisited.           
Is there a Relation Between its Asymmetry and Ventricular Function 
in Coronary Artery Disease?∗ 
 
 
4.1. Introduction 
Blood pool Doppler echocardiography provides a method to measure blood velocities within 
the ventricles and blood vessels [51]. By measuring velocities through the cardiac valves, the 
amount of flow (cardiac output, filling) and the driving pressure gradient, causing the flow, 
can be quantified [51, 53-60], which can be clinically used to assess hemodynamic 
parameters and ventricular function [51, 53-57].  
The profile of the aortic flow velocity curves can be described by the rate of increase 
(acceleration) in velocity, the peak and the time of peak velocity, the mean velocity during 
systole and the ejection duration [51]. Normal outflow shows an asymmetric, triangular 
shaped profile with a fast rise in velocities, peaking around 1/3 of the ejection duration [51]. 
Animal studies have shown that the flow acceleration is a sensitive indicator of the inotropic 
state [61], which was confirmed by clinical research [56, 62]. In LV failure, both a lower and a 
slower increase in velocities (a more rounded Doppler profile with a later peak velocity) was 
observed [51]. Similar changes can be present in normal function but decreased filling (i.e. 
severe mitral stenosis, atrial septal defect, pulmonary hypertension) [51]. Changes in aortic 
velocity curves have been reported in other conditions such as hypertrophic cardiomyopathy 
[63], mitral regurgitation [64] and shock [65]. Furthermore, flow remodelling is regularly seen 
in aortic stenosis where, besides an increasing gradient, the profile changes from a triangular 
shape with an early peak, to a much more rounded form with a later peak in higher grade 
stenoses [51, 59].  
Additionally, it is known that active force development in the myocytes peaks around 1/3 
of the ejection, after which it decreases rapidly [32]. This implies that the early flow 
acceleration is caused by the active contraction, while flow decelerates when force 
development declines. This explains why flow acceleration increases with increased 
contractility. Additionally, research on isolated myocytes suggested that chronic ischaemia 
decreases, but prolongs contraction [49].  
                                                 
∗ With permission from: Cikes M, Kalinic H, Baltabaeva A, Loncaric S, Parsai C, Milicic D, Cikes I, Sutherland GR, 
Bijnens B. The shape of the aortic outflow velocity profile revisited. Is there a relation between its asymmetry and 
ventricular function in coronary artery disease? Eur J Echocardiogr. 2009;10(7):847-57. 
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From this, we hypothesize that in the presence of coronary artery disease, in a subset of 
patients, the overall decrease in contractility caused by regional ischaemia and a slower 
contraction of chronic ischaemic myocytes, might be reflected in the aortic outflow profile, 
particularly in the timing and shape of the LV outflow curve and that these changes are 
related to the severity of contractile dysfunction. In order to study this relation and its 
usefulness in providing diagnostic clinical information, we propose a novel method for 
Doppler signal analysis where various properties of the envelope of the aortic outflow are 
quantified.  
 
 
4.2. Materials and Methods 
4.2.1. Patients  
From a retrospective series of 109 patients which were referred for a routine dobutamine 
stress echo (DSE) at St. George’s hospital (London, UK), 79 (37 male, 42 female, mean age 
62.7±9.4 years) had sufficient visualization of all myocardial walls and interpretable 
continuous Doppler (CW) LV outflow traces and did not have increased outflow velocities at 
rest (baseline) due to either aortic stenosis or the presence of an intra-cavity gradient. 
Furthermore, none of these patients had significant valve disease or left bundle branch block. 
In patients prescribed with beta blocker therapy, it was discontinued three days prior to the 
study.  
Based on the resting wall motion and the response to the dobutamine challenge, the 
patients were divided in 2 subgroups.  
The DSE negative group (DSEneg) consisted of 35 patients without resting wall motion 
abnormalities and a (quantitative) DSE study without signs of inducible ischaemia (9 male, 
26 female, 60.3±8.4 years). 
The DSE positive group (DSEpos) consisted of 44 patients with a DSE study showing 
signs of ischaemic heart disease, either at baseline or during any of the stress levels (28 
male, 16 female, 64.7±9.7 years).  
Additionally, 32 healthy volunteers with no signs or symptoms of cardiovascular disease 
or arterial hypertension were studied at baseline (not undergoing an DSE study) and served 
as a control group (15 male, 17 female, 59.1±11.5 years). The investigation conforms with 
the principles outlined in the Declaration of Helsinki.  
 
4.2.2. Echocardiographic Imaging 
Standard cardiac ultrasound data (including Doppler myocardial imaging (DMI)) at baseline 
(healthy volunteers and patients) and during the DSE (patients) were acquired with a Vivid 
Seven ultrasound scanner equipped with a 2.5-MHz transducer (GE, Horten, Norway). Data 
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were obtained from the parasternal and apical views. For the 2D studies, parasternal long 
and short axis as well as apical two-, three-, four- and five-chamber views were used. Aortic 
outflow CW Doppler traces were acquired from the apical five-chamber view. The 
echocardiographic data were obtained for three complete cardiac cycles during a single end-
expiratory breath hold. 
For the DSE study, dobutamine was infused at rates of 5, 10, 15, 20, 30 and 40 
mcg/kg/min and increased with 3 min steps until reaching 85% of age-predicted heart rate 
(HR) (target HR). The study was interrupted earlier in the presence of induced ischaemia, 
occurrence of severe symptoms, raised blood pressure (BP) or upon reaching target HR. 
Echocardiographic data, together with BP and a 12-lead ECG, were acquired at low (5 
mcg/kg/min), intermediate (20 mcg/kg/min), peak dose (40 mcg/kg/min) and recovery. DMI 
data were simultaneously acquired for post-processing. At each stage, CW Doppler traces of 
aortic flow were additionally acquired. 
The presence of echocardiographic signs of ongoing ischaemic heart disease was 
evaluated by two experienced cardiologists, both by assessment of regional wall motion 
abnormalities [66], as well as by analysis of the underlying DMI data [1].  
Offline analysis was performed using dedicated software (Echopac, GE, Horten, Norway). 
Ejection fraction (EF) was measured by the Simpson biplane method [66]. LV size and mass 
(LVM) were measured [66, 67]; relative wall thickness (RWT) (the sum of posterior and 
septal wall thickness divided by the internal diameter) was calculated as an index of LV 
concentric remodelling [68]. 2D measurements of the basal interventricular septum as well as 
the basal lateral wall were obtained as an additional measure of LV hypertrophy in 
hypertensive heart disease [9].  
 
4.2.3. Doppler Outflow Analysis 
The baseline CW outflow Doppler traces were analyzed for the purpose of this study, both 
manually and semi-automatically. For the manual analysis, the time from onset of aortic flow 
to peak flow (Tman), as well as the ejection time (ETman) and HR were measured. The ratio 
Tman/ETman (indicating the position of the peak within the ejection period), as well as the ratio 
ETman/HR (indicating the duration of ejection within the heart cycle), were calculated. The 
manual analysis was blinded to the DSE results as well as to the automatic analysis.  
The automated quantification of the CW outflow Doppler traces was previously described 
[22]. Doppler traces were not calculated, but rather extracted from the ultrasound image. This 
was done using an image segmentation method. In the first step, the image is converted and 
pre-processed to obtain only the forward velocities. On these images, the velocity envelope 
is detected automatically using thresholding. Next, the onset and the end of the aortic flow 
were manually indicated, thus isolating the outflow profile. Since the Doppler trace has to be 
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continuous and smooth the constraint was implemented forcing the trace to be piecewise 
polynomial. This was done using two cubic polynomial (i.e functions of the form f(x) = ax3 + 
bx2 + c + d) with demands for the first derivatives to be zero at the beginning and end of the 
signal, as well as in the adjacent points where also the second derivative was forced to be 
equal for both of the adjacent polynomials to satisfy the smoothness criteria (Figure 4.1, 
right). From the modelled signals, several parameters describing their shape were extracted. 
Time to peak (Tmod), ejection time (ETmod), rise time (t_rise) and fall time (t_fall) were quantified. 
Rise and fall times were defined from 10% to 90% of the peak (Figure 4.1, bottom). The ratio 
Tmod/ETmod as well as the ratio ETmod/HR were calculated. Additionally, an asymmetry index 
(asymm) was calculated as the difference of the area under the curve of left and right half of 
the spectrum normalized by the overall area. A value for asymm lower than 0.25 was 
considered an indicator of an abnormally symmetrical trace.  
Additionally, the development of an intra-ventricular gradient during DSE was defined as a 
late-peaking LV Doppler velocity profile that exceeded the basal maximum velocity by at 
least 1 m/sec [70]. 
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Figure 4.1. Raw aortic outflow CW Doppler trace (top). The piecewise cubic model fitted 
on the original trace and the properties extracted from it (bottom). 
 
4.2.4. Statistical Analysis 
Continuous variables’ data are expressed as mean value ± SD and the unpaired two-tailed 
Student t-test was performed for comparative analysis. Categorical variables are expressed 
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as a percentage. For categorical variables, comparisons between groups were made using 
the chi-square test. Results were considered significant at P<0.05. A linear correlation was 
used to test the similarity between the manual and automated analysis. 
 
 
4.3. Results 
4.3.1. Patient Group Characteristics and Basic Echocardiography Data  
The basic patient characteristics as well as coronary artery disease severity are provided in 
table 1.  The values of both systolic and diastolic BP were significantly lower in controls while 
the values of systolic BP exceeded normal values in 66% of patients in DSEneg and 71% of 
patients in DSEpos. The heart rate was significantly higher in DSEpos, compared to controls.  
In 15/35 DSEneg patients, a coronary angiogram was performed (which was diagnostically 
inconclusive, or performed due to recurrent chest pain symptoms after previous treatment). 
Five of the DSEneg patients had undergone successful coronary revascularization (one by 
coronary artery bypass grafting - CABG), five had a (remaining) insignificant stenosis. 
Although they had normal rest and stress studies, in six patients, a significant stenosis was 
present at the time of the DSE study (single vessel disease in 1, double in 2, triple in 2 and 
multivessel in 1 patient).  
In DSEpos, significant, non revascularized, coronary artery stenoses were present in 16/44 
patients (6 single vessel disease, 5 double vessel disease, while triple and multivessel 
disease were present in 3 and 2 patients, respectively). Overall, 27/44 patients had previous 
coronary revascularization (14/27 CABG), of these, 9 had a stenosis at time of investigation 
(2 in-stent restenoses and 2 bypass stenoses). 5/44 had an insignificant coronary artery 
stenosis and no angiography data were available for the remaining 5/44 patients.  
The basic echocardiographic measurements are given in table 2. LV mass (ASE formula), 
was significantly higher in DSEpos compared to DSEneg and controls (p=0.01 and p<0.00001, 
respectively) mostly due to larger LV cavity measures. The size of the LV cavity was 
significantly smaller in DSEneg, both in end systole as well as in end diastole. RWT, an 
indicator of concentric hypertrophy, was significantly larger in DSEneg. Patients in DSEneg and 
DSEpos had a notable basal septal thickening/bulge, measuring in average 1.3±0.3 cm, while 
it was significantly smaller in the controls. Furthermore, EF was significantly higher in DSEneg 
compared to the other two groups (p<0.000001 vs. controls and DSEpos). Ejection fraction 
was preserved in all healthy volunteers and patients in DSEneg, while it was reduced in 39% 
of the DSEpos patients. 
Notably, an LV dynamic intracavitary gradient was induced by DSE in 71.4% of DSEneg 
patients and 18.2% of DSEpos. In patients developing an intracavitary gradient, RWT 
(p<0.004 vs. no gradient, p<0.000001 vs. controls) and EF (p<0.0001 vs. controls, 
 46
p<0.00001 vs. no gradient) were significantly larger than in patients who did not develop an 
intracavitary gradient during DSE, or controls.  
 
  
control group 
(n=31) 
DSEneg (n=35) DSEpos (n=44) 
Age (years) 59.0±11.5 60.3±8.4 64.7±9.7* 
male/female 15/17 9/26 28/16 
SBP rest (mmHg) 119.7±13.2 154.1±22.3† 146.3±16.7† 
DBP rest (mmHg) 73.3±6.8 82.2±10.9‡ 79.6±11.0§ 
HR rest (/min) 62.9±10.8 67.5±11.2 70.9±10.7§ 
CABG (pts) - 1 14 
PCI (pts) - 4 15 
Insignificant stenosis (pts) - 5 5 
single vessel (pts) - 1 6 
double vessel (pts) - 2 5 
triple vessel (pts) - 2 3 
multi vessel (pts)  1 2 
 
Table 4.1. Basic patient characteristics 
* P<0.05 vs. DSEneg; †P<0.0001 vs. control, ‡ P<0.001 vs. control, § P<0.05 vs. control. 
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control group 
(n=31) DSEneg (n=35) DSEpos (n=44) 
LVIDd (cm) 4.9±0.5 4.5±0.5* 5.3±0.9†‡ 
LVIDs (cm) 3.0±0.5 2.7±0.6§ 3.5±0.9§‡ 
IVSd (cm) 0.9±0.2 1.1±0.2† 1.1±0.3† 
LVPWd (cm) 0.8±0.2 1.0±0.3† 0.9±0.2† 
IVS bulge (cm) 1.1±0.2 1.3±0.3† 1.2±0.3§ 
lateral wall (cm) 0.9±0.1 1.0±0.2§ 0.9±0.2 
RWT 0.35±0.06 0.47±0.08* 0.38±0.10‡ 
EF (%) 65.4±5.6 75.6±7.9* 57.5±13.9†‡ 
LV mass (g) 167.1±53.3 177.8±58.3 241.8±89.5*║ 
LV mass ASE (g) 145.2±42.7 158.1±46.3 204.4±72,1*║ 
inducible gradient (pts) - 25 8 
Table 4.2. Echocardiographic measurements 
P<0.0001 vs. control, † P<0.005 vs. control, ‡P<0.0001 vs. DSEneg, § P<0.05 vs. 
control, ║P<0.001 vs. DSEneg 
 
Figure 4.2. Raw CW Doppler trace and extracted profile from the control group (left), DSE 
negative group (middle) and DSE positive group (right). 
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control group 
(n=31) DSEneg (n=35) DSEpos (n=44) 
asymm 0.33±0.06 0.35±0.07 0.30±0.08* 
asymm < 0.25 (%) 0.0 2.9 27.3 
ETmod  293.4±59.3 329.4±33.6† 305.3±37.7* 
ETman 296.0±19.4 324.8±40.5† 304.8±33.5‡ 
ETmod/HR 4.55±1.30 5.12±1.11 4.62±1.22 
ETman/HR 4.59±0.90 5.06±1.27 4.60±1.16 
Tmod 65.66±13.50 65.16±13.81 74.50±18.93 §‡ 
Tman 55.33±10.42 64.49±16.03§ 68.73±15.97║ 
Tmod/ETmod 0.215±0.036 0.199±0.046§ 0.244±0.055§* 
Tman/ETman 0.187±0.036 0.201±0.055 0.228±0.057†‡ 
T_rise 0.032±0.008 0.032±0.008 0.037±0.010§‡ 
T_fall 0.153±0.013 0.168±0.025† 0.146±0.026* 
Table 4.3. Properties extracted from aortic Doppler traces 
* P<0.005 vs. DSEneg, † P<0.005 vs. control, ‡ P<0.05 vs. DSEneg, § P<0.05 vs. control, 
║P<0.0001 vs. control. 
 
4.3.2. Doppler Outflow Analysis 
Figure 3.2 shows typical examples (both the raw Doppler trace and the extracted profile) 
from the 3 subgroups. The properties extracted from the aortic flow are shown in table 4.3.   
Ejection time corrected by heart rate (ETman or ETmod) was not different among the three 
groups. The absolute time to peak (Tmod) was significantly higher in DSEpos, followed by 
DSEneg and the controls.  
The relative time to peak Tmod/ETmod was the longest in DSEpos; notably, it was found to be 
shorter in DSEneg compared to controls.  
Rise time t_rise was longest in DSEpos compared to DSEneg (p=0.01) and controls (p=0.02). 
Fall time tfall was shortest in DSEpos, though it was the longest in DSEneg (p<0.005 vs. controls 
and DSEpos). Furthermore, t_fall was notably prolonged in the patients who developed an 
intracavitary gradient during DSE (0.17±0.03), compared to the ones without an inducible 
gradient (0.15±0.03, p<0.01) and controls (0.15±0.01, p<0.03).  
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Asymm was the lowest in DSEpos, followed by controls and DSEneg (Table 4.3). An 
abnormally symmetric profile (asymm<0.25) was found in 1/35 (2.9%) of the DSEneg patients 
and in 12/44 (27.3%) of the DSEpos patients, while in none of the controls. 
The relations between the EF and asymm, Tmod/ETmod, t_rise and t_fall, as well as LVIDd vs. 
asymm, Tmod/ETmod, trise are shown in figure 4.4 and figure 4.5, respectively. No significant 
correlation was found between t_rise and t_fall (r=0.19). Moreover, neither asymm, nor trise or 
tfall seemed to be influenced by systolic blood pressure (r=0.08). 
The difference in values of asymm, Tmod/ETmod, t_rise and t_fall among the three patient 
groups are shown in figure 6.  
In the patients who developed an intracavitary gradient during DSE, t_fall was significantly 
prolonged while Tmod/ETmod was significantly shorter compared to the group of patients 
without an inducible intracavitary gradient by DSE (figure 4.7). 
In the subgroup of patients who underwent coronary angiography, the sensitivity of the 
DSE study in detecting CAD was 76%, while its specificity was 31%. In the same subgroup 
of patients, the sensitivity of the semi-automated method (using the asymmetry index) was 
35%, while its specificity was 88%. A combined sensitivity of DSE and the semi-automated 
method (using the asymmetry index) was 58%, while the specificity was 67%. Within the 
DSEpos and DSEneg groups, the sensitivity of the asymmetry index in detecting the DSE study 
outcome was 27%, while the specificity was 97%.  
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Figure 4.3. The correlation between the manual and automated measurements of ejection 
time and time to peak velocity. 
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Figure 4.4. The correlation between EF and asymm, Tmod/ETmod, t_rise and t_fall. 
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Figure 4.5. The correlation between LVIDd and asymm, Tmod/ETmod, t_rise. 
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Figure 4.6. The values of asymm, Tmod/ETmod, t_rise and t_fall among the three patient groups. 
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Figure 4.7. The values of EF, RWT, t_fall and Tmod/ETmod among the patients grouped in 
regard to inducible intracavity gradient. 
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4.4. Discussion 
In this study, we have observed that the aortic outflow velocity profile is altered in the 
presence of coronary artery disease where in an import portion of patients the flow profile 
becomes much more symmetrical and rounded, whereas it is clearly asymmetrical and 
triangular in normal subjects. On average, in CAD, the rise time prolongs, the time to peak 
velocity is delayed and the fall time shortens. 
Aortic outflow is the result of pressure development and deformation of the LV. 
Generation of pressure within the cavity of the LV is a direct consequence of active force 
development within the myofibres. Once initial force is developed by the contractile elements, 
the ventricle can increase its internal pressure up to the point high enough to open the aortic 
valve. From this moment, the shortening of the contractile elements will decrease the cavity 
size so that its internal blood content is ejected [1, 71]. The velocities with which the blood is 
ejected through the aortic valve depend on the pressure gradient. In the absence of an aortic 
stenosis, this gradient is determined by the developed LV pressure and the pressure in the 
aorta, which depends on the peripheral circulation and the aortic stiffness. In the absence of 
afterload changes, aortic outflow should directly reflect active force development and the 
resulting myocardial deformation. Sabbah et al. have shown that the peak acceleration of 
aortic blood flow assessed non-invasively in patients with a CW Doppler velocity meter is a 
useful indicator of global LV performance, as assessed by EF, while neither peak velocity nor 
the systolic velocity integral related as closely to EF [62]. This was also shown in 
experimental setups [61]. An analysis of aortic wave intensity and aortic velocities during a 
dobutamine infusion showed the increased acceleration of the velocity and a more 
asymmetrical profile with faster deceleration, mainly due to the interaction of the forward and 
backward waves in the aorta [72]. It was also shown that dobutamine provokes an increase 
in aortic acceleration, although the increase was significantly lower in patients with CAD. 
However, no difference in aortic acceleration was found between patients and controls at 
baseline [73]. 
Additionally, in a pig model of myocardial hibernation, Bito and co-authors demonstrated 
that isolated chronically ischaemic myocytes show a reduced and slowed contraction when 
compared to normal myocytes and that they show a significant reduction in active force 
development [49, 74]. Furthermore, several studies on long axis function have demonstrated 
that, in areas affected by CAD, the onset of contraction is delayed, the overall amplitude and 
velocity of contraction may be reduced and its duration prolonged [75-77].  Hatle and co-
authors showed that the relative timing of the maximal aortic flow occurred later in LV heart 
failure [59]. The same study showed the lowest values of time to peak velocity in patients 
with hyperkinetic heart syndrome or with considerable aortic regurgitation.  
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In this study, we hypothesize that the presence of coronary artery disease can result in a 
global decrease in contractility such that the LV is not able to generate the required stroke 
volume anymore when developing (normal) short-lived active contraction force. In order to 
generate enough stroke volume the whole LV will prolong the development of contractile 
force, which, besides a slower increase in the blood velocities through the aortic valve, will 
also result in a longer duration of aortic acceleration and a more symmetrical profile of which 
the bulk of the flow shifts towards the later part of the ejection period. 
This remodelling of the aortic velocity profile can be quantified based on the timing and 
the overall shape of the LV outflow curve. In this study we have analyzed CW Doppler traces 
in patients with and without signs of ischaemic heart disease, as assessed by quantitative 
DSE. We have implemented an automated analysis tool, using modelling of the velocity 
envelope, to measure the time intervals relevant for determining later peaking of the outflow 
traces in CAD.  
Our results show that the shape of the aortic outflow trace may reflect decreased 
contractility: the traces of patients within DSEpos show a tendency towards a more 
symmetrical, later peaking and faster falling curve than in DSEneg patients and normals. 
There was a clearly positive correlation of the relative timing of the peak velocity 
(Tmod/modmod) with EF and a negative one with LVIDd, as a marker of LV dilatation. 
Furthermore, we observed that an asymm<0.25, indicating a markedly more symmetrical 
trace, was present in only 2.9% patients in DSEneg and 27.3% of patients in DSEpos while it 
was greater than 0.25 in all controls. Moreover, asymm proved to be a valid indicator of 
contractility: it correlated well with EF and had a somewhat weaker, negative correlation with 
LVIDd.   
Although the acceleration of the aortic outflow was previously suggested as a marker of 
contractility [62], the aortic rise time t_rise showed a weaker correlation both with EF and 
LVIDd, compared to Tmod/modmod and our measure of curve symmetry (asymm), suggesting 
that not only the initial acceleration, but the whole velocity profile has to be considered to 
describe LV function. 
While we hypothesize that a more symmetrical aortic outflow profile indicates decreased 
global contractility, surprisingly, we found that the patients within the DSEneg group, on 
average, showed a more asymmetrical aortic flow pattern with a shorter Tmod/modmod and 
prolonged t_fall when compared to controls. This group of patients also had a significantly 
higher RWT and EF, as well as higher values of SBP and DBP, compared to the other two 
groups. Additionally, in this DSEneg group, an LV dynamic intracavitary gradient was induced 
by DSE in as much as 71% of the patients while this was observed in only 18% in the DSEpos 
group. This characteristic late and large increase in outflow velocities reflects the dynamic 
nature of an additional pressure gradient developed within the LV when the cavity size 
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decreases during ejection [78, 79]. This gradient was previously noted in 21% of patients in a 
series of 57 patients undergoing DSE and was associated with a significantly higher resting 
EF but no evidence of a significant difference in history of hypertension, LV hypertrophy, or 
signs of CAD was present [70]. In another series, the late increase in outflow tract velocities 
was associated with signs of basal septal hypertrophy and smaller LV cavities [80]. In a 
series of 394 patients, 17.5% developed a significant LV outflow gradient, which was 
associated with asymmetrical septal hypertrophy and a lower frequency of wall motion 
abnormalities [81]. Overall, in our group of patients, a significant prolongation of the duration 
of tfall was present in patients who developed an intracavitary gradient compared to the ones 
which had no inducible gradient or controls. This, together with the increased hypertrophy 
and EF, would let us hypothesize that the patients who develop a dynamic gradient during 
the DSE have actually increased contractility at baseline and thus indeed show a more 
asymmetric outflow profile with an earlier peak. The hypertrophy and associated increased 
contractility in these patients might be caused by the transient, exercise induced, increased 
pressure overload due to the development of the gradient. The potential to develop a 
dynamic gradient might be triggered by the localized basal septal hypertrophy, induced by 
the presence of hypertension [9]. 
 
 
4.5. Clinical Perspective 
The goal of this study was not to present another non-invasive parameter to be used in 
discrimination CAD patients, but rather to address flow remodelling as a consequence of 
cellular and force remodelling which occurs in ischaemic heart disease. We have shown that 
decreased overall contractility results in a more symmetrical outflow velocity profile. In clinical 
practice, the presence of an abnormally symmetrical profile in an individual patient would 
thus suggest that the global development of contractile force has been remodelled to cope 
with the decreased output resulting from decreased contractility. On the other hand, a very 
asymmetrical and early peaking profile implies increased contractility, which, in the presence 
of (regional) hypertrophy, might induce a dynamic intracavitary gradient. Additionally, these 
patients are prone to Tako-Tsubo cardiomyopathy [82]. 
Incorporating parameters describing the profile of the outflow trace, in the clinical 
echocardiographic measurements thus provides additional information on myocardial 
function 
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4.6. Limitations 
Left ventricular outflow velocities represent the pressure gradient between the LV and aorta 
and are thus influenced by either of them. This implies that changes in the peripheral vessel 
tree could influence the flow profile. However, a dynamically increasing resistance in the 
vessel tree, associated with decreased compliance, as expected in CAD, would reduce late 
velocities while the presence of high late velocities should thus be related to prolonged LV 
pressure development. Changes in the isometric contraction duration in itself, would not 
change the measurements since we start quantifying from the opening of the valve. 
However, a lengthening of the isometric contraction time would also be expected with a 
decreased contractility, which would be reflected again in a slower rise time and later 
peaking, as we observe. 
Although contractility was not measured directly, there is a strong body of evidence 
proving that DSE testing, especially including information on changes in local deformation, is 
indicative of increase in contractility. Furthermore, as this was a retrospective study on 
routine clinical data, catheterisation measurements of LV contractility were not available, nor 
was sufficient mitral regurgitation present in most of the patients in order to measure Dp/dt. 
Therefore, we have chosen to subgroup the patients based on the DSE response rather than 
angiographically proven CAD, which then served as an adjunctive marker of LV contractility, 
Moreover, the current study was performed using CW Doppler, which is also influenced by 
velocities in the LV cavity (such as the development of a dynamic gradient). Finally, although 
dobutamine mimics exercise, its effects are quite different in terms of loading as it decreases 
preload and afterload. Therefore, identical effects should not be assumed for exercise 
echocardiography. 
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Chapter 5 
The Symmetry of the Shape of the Instantaneous Peak Velocities 
in Aortic Stenosis: Does it Predict Functional Recovery after Aortic 
Valve Replacement?∗ 
 
5.1. Introduction 
Severe aortic stenosis (AS) is often masked in asymptomatic patients although subclinical 
systolic dysfunction with preserved ejection fraction may already be present [83]. It is a 
challenge to recognize patients with subclinical myocardial dysfunction in order to operate 
early enough to prevent irreversible myocardial damage, but not so early as to subject them 
to unnecessary risks. The optimal timing of valve replacement surgery is often unclear and 
mostly not obvious from regularly used measurements of ventricular function, suggesting the 
need for improved understanding and assessment of the potentially induced changes in 
ventricular function.  
Forward flow across the aortic valve is determined by factors such as LV contractility, 
valve properties (valve area) as well as (systemic) afterload. Therefore, the Doppler trace of 
aortic outflow (instantaneous peak velocity) in AS should reflect not only stenosis severity, 
but potential LV functional damage as well. Although the Doppler pressure gradient 
measured over a stenotic valve is indicative of stenosis severity, it often does not relate to 
myocardial function or changes in contractility resulting from myocardial damage, as can be 
found in low gradient, severe AS. Furthermore, it has been shown that, despite preserved 
EF, paradoxical low-flow, low-gradient severe aortic stenosis is associated with higher 
afterload and reduced survival [84]. 
Beside data on blood flow velocities and pressure gradients, it has been suggested that 
the profile of Doppler traces of aortic outflow presents further insight into disease severity in 
patients with AS [51, 85]. The profile of the aortic flow velocity curves can be described by 
the rate of increase (acceleration) in velocity, the peak and the time of peak velocity, the 
mean velocity during systole and the ejection duration [51]. Normal outflow shows an 
asymmetric, triangular shaped profile with a fast rise in velocities and peaking around 1/3 of 
the ejection duration [51].  
With mild AS and high flow, the peak velocity occurs early in systole, while in cases of 
severe stenosis the peak is reached in midsystole, presenting with a more symmetrical curve 
                                                 
∗ From: Cikes M, Kalinic H, Hermann S, Loncaric S, Milicic D, Beer M, Hatle L, Cikes I, Sutherland G, 
Weidemann F, Bijnens B. The Symmetry of the Shape of the Instantaneous Peak Velocities in Aortic Stenosis: 
Does it Predict Functional Recovery after Aortic Valve Replacement? Submitted for review.  
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[85]. Furthermore, it has been shown that in acute aortic constriction, the myocardium 
generates an active force of normal magnitude, but with a longer duration, while in chronic 
AS a bigger and longer force occurs [86]. Thus, to compensate for the obstruction to flow 
occurring in acute aortic constriction, the aortic instantaneous peak velocity curve will 
become more prolonged and increasingly symmetric in shape when the force development is 
prolonged. 
The time in systole at which the peak pressure difference occurs is later with increasing 
obstruction, but is also influenced by the course of the LV pressure curve. It is known that 
active force development in the normal myocytes peaks around 1/3 of the ejection, after 
which it decreases rapidly [32]. This implies that the early flow acceleration is caused by 
active contraction, while flow decelerates when force development declines. This explains 
why flow acceleration increases with increased contractility [87]. There are some suggestions 
that the timing of myocyte contraction might be altered with a decrease in function [49]. This 
might be the reason why, with increasing severity of aortic stenosis, a concomitant change in 
the shape and duration of both the local deformation and the aortic outflow blood velocities 
can be observed. Therefore, in addition to the differences in the severity of obstruction, 
changes in the LV and aortic pressure curves as a consequence of changes in contractility 
and peripheral resistance may influence the pressure difference and thus the course of the 
maximal velocity curve [51].  
Based on this, we hypothesize a relation between the shape of aortic instantaneous peak 
velocities and myocardial function in AS where myocardial contractility can be prolonged, 
resulting in a more symmetrical cardiac outflow as reflected from the Doppler signal. 
 
 
5.2. Methods 
5.2.1. Patients 
We studied 34 patients undergoing aortic valve surgery for severe AS (as defined by the 
European Society of Cardiology guidelines) [88] preoperatively (PRE) and 9 months 
postoperatively (POST). This group consisted of 16 female and 18 male patients, mean age 
69.4±9.3 years.  
The control group consisted of 29 healthy volunteers with no signs or symptoms of 
cardiovascular disease or arterial hypertension (15 female, 14 male, mean age 63.1±10.5 
years). All patients gave written consent for CMR and echocardiography studies including 
digital data storage and systematic analysis of the data. The study complies with the 
Declaration of Helsinki and was approved by the University Hospital Wuerzburg review 
committee. 
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5.2.2. Echocardiographic Imaging 
Standard cardiac ultrasound data were acquired with a Vivid Seven ultrasound scanner 
equipped with a 2.5-MHz transducer (GE, Horten, Norway). Data were obtained from the 
parasternal and apical views. For the 2D studies, parasternal long and short axis as well as 
apical two-, three-, four- and five-chamber views were used. Aortic outflow CW and left 
ventricular outflow pulsed wave Doppler traces were acquired from the apical five-chamber 
view (LV outflow pulsed wave Doppler was acquired for AVA measurements, as described 
later). The echocardiographic data were obtained for three complete cardiac cycles during a 
single end-expiratory breath hold. 
Offline analysis was performed using dedicated software (Echopac, GE, Horten, Norway). 
LV size and mass were measured from the M-mode images [66, 67]. EF was measured by 
the Simpson biplane method [66]. CW Doppler traces of the aortic outflow were analyzed by 
planimetry of the Doppler envelope in order to obtain the mean systolic transaortic pressure 
gradient (PG mean), which, as the maximal systolic transaortic pressure gradient, was 
calculated by the modified Bernoulli equation. Aortic valve area (AVA) was calculated from 
the continuity equation [89, 90]. The peak pulmonary artery pressure was measured from the 
pressure gradient calculated using the simplified Bernoulli equation of the tricuspid 
regurgitation jet peak velocity and adding the right atrial pressure as estimated from the 
inferior vena cava diameter and respiratory collapse, where available. The LV ejection time 
index was calculated as previously described [91].  
  
5.2.3. Doppler Outflow Analysis 
The aortic outflow CW Doppler traces were analyzed semi-automatically. The approach was 
previously described [69]. Figure 5.1 (left) shows the original Doppler image. In the first step, 
the image was converted and pre-processed to obtain only the forward velocities. On these 
images, the velocity envelope was detected automatically using thresholding. Next, the onset 
and the end of the aortic flow were manually indicated, thus isolating the instantaneous peak 
velocity profile. In order to eliminate the non-physiological noise and artefacts (mainly 
corresponding to the “valve clicks”) a piecewise cubic model was fitted to the trace. From the 
modelled signals, several parameters describing their shape were extracted. Time to peak 
(Tmod), ejection time (modmod), rise time (T_rise) and fall time (T_fall) were quantified. Rise 
and fall times were defined from 10% to 90% of the peak (Figure 5.1, right). The ratios 
Tmod/ETmod as well as ETmod/R-R were calculated. Additionally, an asymmetry index (asymm) 
was calculated as the difference of the area under the maximum velocity curve contained in 
the first and second half of the ejection period normalized by the overall area.  
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Figure 5.1. Aortic outflow Doppler image (left), the piecewise cubic model fitted on the 
original trace and the parameters extracted from it (right). 
 
5.2.4. Cardiac Magnetic Resonance Imaging 
CMR was performed on Siemens Sonata – Avanto (Erlangen, Germany) or Phillips Gyroscan 
ACS-NT (Best, The Netherlands) 1.5 T whole-body scanners with dedicated cardiac coils. 
Breath-hold cine images were acquired in multiple short-axis and three long-axis slices with 
steady-state free precession sequences. Ventricular coverage was achieved with contiguous 
10 mm-thick slices or 7 mm slices (2–3 mm gap). Images for late enhancement (LE) 
diagnostics were acquired 15 min after the injection of gadopentetate dimeglumine 
(Magnevist; Schering, Berlin, Germany; 0.2 mmol per kilogram of body weight) with a breath-
hold segmented inversion-recovery sequence (inversion time 240–300 ms) acquired in the 
same views. 
 
5.2.5. Statistical Analysis 
Continuous variables’ data are expressed as mean value ± SD. For comparative analysis, an 
unpaired two-tailed Student t-test was performed between groups with unequal distribution, 
while a paired test was performed between the PRE and POST groups. Categorical variables 
are expressed as a percentage. For categorical variables, comparisons between groups 
were made using the chi-square test. Results were considered significant at p<0.05. A linear 
correlation was used to test the similarity between the relevant parameters. Comparisons of 
the areas under the receiver operating characteristic (ROC) curves for patients with 
postoperative improvement of EF as well as those with postoperative stagnation or 
deterioration in EF were performed to assess diagnostic accuracy of asymm, AVA and PG 
mean.  
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5.3. Results 
5.3.1. Patient Group Characteristics and Basic Echocardiography Data  
The basic patient characteristics are given in table 5.1. The preoperative age of the patients 
did not differ significantly from the control group. SBP, DBP and HR values POST were 
significantly higher compared to the control group. The NYHA class was improved in most 
patients after AVR. Most of the patients suffered from arterial hypertension (94%), less from 
diabetes (24%). In the PRE group, signs of CMR LE were demonstrated in 72% of the 
patients in which such a study was performed. Table 5.2 shows the obtained 
echocardiographic measurements. No significant difference was found in LV cavity size 
between the three groups, although a tendency toward reduction in LV cavity size was 
present postoperatively. The patients presented with marked concentric hypertrophy 
preoperatively, which was significantly reduced postoperatively, although LV wall thickness 
was still significantly higher, compared to the control group (p<10-8), as was the LV mass 
(p<0.00001) (Table 2). EF was significantly lower in the PRE and POST groups (p<0.05, 
compared to the controls), tending to normalize after AV surgery (p<0.05 POST vs. PRE). 
Notably, only 8.8% of the patients had EF PRE values ≤45% (Table 5.2). The values of AVA, 
PG mean, maximal systolic transaortic PG and Vmax have significantly improved after AVR, 
compared to the PRE values (p<10-8 for all parameters). No significant change was noted in 
PAP POST compared to PRE (Table 5.2). No significant correlation was found between EF 
PRE and EF POST-PRE (r=-0.44) 
 
control group 
(n=29) 
Aortic stenosis 
PRE (n=34) 
Aortic stenosis 
POST (n=34) 
Age (years) 63.1±10.5 69.4±9.3 71.4±9.2* 
male/female 14/15 18/16 18/16 
SBP rest (mmHg) 121.0±11.9 128.3±15.8 131.9±13.9* 
DBP rest (mmHg) 72.7±6.2 79.9±8.4† 77.6±9.4* 
NYHA 1.0±0.0 3.0±0.6 2.0±0.9‡ 
MI (no pts/%) 0/0 3/34=8.8% 3/34=8.8% 
DM (no pts/%) 0/0 8/34=24% 8/34=24% 
HTN (no pts/%) 0/0 32/34=94% 32/34=94% 
CMR LE (no pts/%) -/- 13/18=72% 14/19=74% 
Table 5.1. Basic patient characteristics 
* P<0.05 vs. control; † P<0.002 vs. control, ‡ P=0.00001 vs. PRE. 
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control group 
(n=29) 
Aortic stenosis 
PRE (n=34) 
Aortic stenosis 
POST (n=34) 
LVIDd (cm) 4.9±0.5 4.9±0.9 4.7±0.7 
LVIDs (cm) 3.0±0.5 3.3±0.9 3.3±0.7 
IVSd (cm) 0.9±0.2 1.4±0.2† 1.2±0.1†‡ 
LVPWd (cm) 0.8±0.2 1.4±0.2† 1.1±0.1†‡ 
LV mass ASE (g) 141.8±43.1 292.0±97.2† 205.4±58.9§# 
EF (%) 65±6 59±9║ 61±8║# 
LV EF ≤45% (%) 0 8.8 3.4 
AVA 3.54±0.66 0.80±0.17§ 1.93±0.45║‡ 
PG max (mmHg) 6.08±1.32 78.74±21.75† 23.94±8.11†‡ 
PG mean (mmHg) 3.14±0.53 48.74±13.27† 13.58±5.04†‡ 
AV Vmax (m/s) 1.02±0.32 4.26±0.70† 2.32±0.45║‡ 
PAP (mmHg) 13.73±3.16 33.65±10.74║ 31.65±8.39║ 
Table 5.2. Echocardiographic measurements 
* P<0.0000002 vs. control, † P<0.00000001 vs. control, ‡ P<0.00000001 vs. PRE, § 
P<0.00005 vs. control, ║ P<0.05 vs control, # P<0.05 vs. PRE 
 
5.3.2. Doppler Outflow Analysis 
Figure 5.2 shows typical examples of the extracted PRE and POST profiles in patients with 
and without postoperative EF recovery.  
Table 5.3 shows the parameters extracted from the aortic flow traces. Asymm was the 
lowest in the preoperative patient group indicating the most symmetrical traces, while its 
values have risen significantly after AVR. Asymm was the highest within the control group. 
Notably, 91.2 % of the AS patients had an abnormally symmetric trace (asymm <0.25) before 
aortic valve surgery, while only 34.5% of the AS patients retained such symmetric traces 
after AVR. None of the control group patients had such abnormal traces.  
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Figure 5.2. The piecewise cubic model of aortic outflow. A typical symmetric aortic outflow 
trace in a patient with AS showing no ejection fraction recovery postoperatively (top; 
preoperative trace – left, postoperative trace - right) and an asymmetric aortic outflow trace in 
a patient with AS showing ejection fraction recovery postoperatively (bottom; preoperative 
trace – left, postoperative trace - right). 
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control group 
 (n=29) 
Aortic stenosis 
PRE (n=34) 
Aortic stenosis 
POST (n=34) 
asymm 0.33±0.06 0.16±0.06* 0.28±0.08†‡ 
asymm < 0.25 (%) 0.0% 91.2% 34.5% 
T_rise 0.032±0.008 0.054±0.013* 0.035±0.011§ 
T_fall 0.153±0.013 0.127±0.026║ 0.138±0.019†# 
Tmod 65.7±13.5 103.2±21.5* 68.5±18.3‡ 
ETmod 303.5±21.5 315.7±40.3 284.6±33.3†# 
ETmod/ R-R 0.316±0.044 0.381±0.078† 0.328±0.051# 
Tmod/ETmod 0.22±0.04 0.32±0.06* 0.12±0.03*‡ 
LVETI 410.5±17.1 432.1±43.1†s 402.7±32.2# 
HR (/min) 62.9±10.8 73.2±15.2† 69.5±10.4† 
 
Table 5.3. Properties extracted from aortic Doppler traces and time intervals 
* P<0.00000001 vs. control, † P<0.05 vs. control, ‡ P<0.00000001 vs.PRE, § P<0.00001 vs. 
PRE, ║P<0.00001 vs. control, # P<0.05 vs. PRE 
 
T_rise was the longest in the PRE group, with a significant shortening in the POST group, 
while it was the shortest in the control group. Similarly, T was the longest in patients before 
surgery and became much shorter after AVR. T_fall, on the contrary, was the shortest in the 
PRE group, rising significantly in the POST group while it was the longest within the control 
group (Figure 5.3).  
Relative ejection time modmod/R-R was the most prolonged in the PRE group, showing 
normalization in the POST group. Finally, the relative time to peak Tmod/ETmod and LVETI 
were the longest before AVR, shortening after surgery to values lower than within the control 
group.  
Notably, within the PRE group of patients, a significant correlation was found between 
asymm PRE and change in EF POST-PRE (r=0.65, P<0.05, figure 5.4) while no correlations 
were found between neither AVA nor PG mean and the change in EF POST-PRE (r=0.05 
and r=0.04, respectively, p>0.05). Figure 5.5. demonstrates the ROC curves for asymm, AVA 
and PG mean in relation to EF POST-PRE. Asymm PRE values ≥ 0.15 demonstrated 95.2 % 
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specificity in detecting improvement in EF after surgery. Conversely, all patients showing no 
improvement or deterioration of EF after surgery had asymm PRE < 0.15 (100% sensitivity).  
Finally, asymm PRE did not correlate significantly with PG mean PRE (r=0.20), while the 
patients with higher values of asymm PRE all showed improvement in EF POST-PRE 
(positive delta EF), regardless of PG_mean PRE (figure 5.6). A positive correlation was 
present between asymm PRE and AVA PRE within the subgroup of patients which had an 
improvement in EF POST-PRE (r=0.62), while such a correlation was not found in the 
patients with an EF POST-PRE stagnation or deterioration (figure 5.7).  
 
In the subgroup of patients with asymm PRE ≥ 0.15 (which all improved EF 
postoperatively), CMR LE was present in 50% of these patients. Conversely, in the subgroup 
of patients with asymm PRE < 0.15, CMR detected LE in 90.9% of these patients. Finally, 
after AVR, values of asymm had increased to ≥ 0.15 in all patients. Nevertheless, 10 patients 
retained asymm < 0.25. Preoperative CMR data were available in 6/10 patients and all of 
these patients showed signs of LE detectable on CMR imaging.  
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Figure 5.3. Values of properties extracted from the aortic flow traces. 
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Figure 5.4. Positive correlation between asymm values PRE compared to EF POST-PRE. 
  
 
Figure 5.5. Receiver-operating characteristic analysis for the asymmetry index, PG mean 
and AVA comparing AS patients with postoperative improvement of EF and AS patients with 
postoperative stagnation or deterioration of EF. 
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Figure 5.6. Absence of significant correlation between the asymm values and PG mean PRE. 
Notably, the patients with higher asymm PRE all showed improvement in EF POST (circles - 
positive delta EF), while the patients with lower asymm demonstrated no change or even a 
decrease in EF POST (x sign – neg/zero delta EF), both regardless of PG mean PRE. 
R=0.626
R=0.045
0.2
0.4
0.6
0.8
1
1.2
1.4
0.05 0.1 0.15 0.2 0.25 0.3
neg/zero delta EF
positive delta EF
AV
A 
pr
e 
su
rg
er
y
asymm pre surgery  
Figure 5.7. A positive correlation between the preoperative values of the asymmetry index 
and the preoperative aortic valve area within the subgroup of patients showing an 
improvement in postoperative EF. Such a correlation was not found in the patients with a 
postoperative EF stagnation or deterioration. 
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5.4. Discussion 
In the present study, we have shown that the aortic instantaneous peak velocity Doppler 
traces in aortic stenosis vary in the degree of symmetry and that this is predictive of 
functional recovery after AVR. The current study has shown that: I) the shape of the aortic 
instantaneous peak velocity in patients with AS is markedly more symmetric than in the 
control group; II) an increase in trace symmetry before AVR is predictive of poorer EF 
recovery 9 months after surgery: all patients with asymm PRE <0.15 showed no 
improvement or even deterioration of EF postoperatively. Interestingly, no significant 
correlations were found between classical indices of stenosis severity such as PG mean nor 
AVA and change in EF pre- and postoperatively, neither did the preoperative values of EF 
influence postoperative EF recovery.  
Current guidelines on AS are largely based on Doppler measurements of transaortic 
gradients, being an easily quantifiable measure of stenosis severity [88]. Nevertheless, due 
to their flow dependency, pressure gradients are a suboptimal measure of stenosis severity. 
Therefore, as demonstrated by multiple studies, measurements of aortic valve area would 
theoretically be an ideal way of AS severity quantification, although they are less robust and 
have potential inaccuracies as well [90, 92, 93]. Having such potential setbacks in mind, the 
current guidelines suggest combining several different echocardiographic parameters in the 
assessment of AS severity, as well as in the prediction of disease progression and outcome. 
Owing to the lack of a haemodynamic gold standard, it has been recognized that clinical 
outcome is the only end point available for defining stenosis severity [94], as well as that 
poor outcome can be independently predicted by multiple factors such as age, chronic renal 
failure, aortic valve velocity as well as significant valve calcifications in the case of mild 
/moderate AS [70, 95].   
In the absence of afterload changes, instantaneous peak velocities should directly reflect 
active force development and the resulting myocardial deformation, while in severe AS it is 
influenced by the pressure gradient across the stenotic valve as well. Therefore, the shape of 
the instantaneous peak velocities in AS reflects both stenosis severity, as well as LV 
functional changes and myocardial damage. The relation between the late peaking features 
of aortic outflow and AS has been recognized some time ago. Bonner et al have found that a 
higher ejection time index, decreased maximum rate of carotid pulse rise and later timing of 
the peak of the systolic murmur were highly suggestive of severe AS [96], while Wranne et al 
described midsystolic peaking of the aortic Doppler signal in cases of severe stenosis [85]. 
Apart from demonstrating that the maximum aortic velocity occurred later in ejection in 
patients with severe AS, a temporal discrepancy of maximum left ventricular outflow tract 
velocity and aortic velocity was shown by Beauchesne et al, such that the left ventricular 
outflow tract velocity occurred later during ejection, while they occurred simultaneously in 
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control patients [97]. In another study, Agatston and co-workers have studied the relation 
between the modified time to peak/modified LV ejection time derived by Doppler and the 
peak to peak catheterization gradient. They have found that a ratio of 0.3 distinguished 
patients with a peak-to-peak gradient of <50 mmHg from those with a larger gradient in all 
but one patient which also had poor LV function. This patient actually had a symmetric trace 
(higher modified time to peak/modified LV ET than expected), which indeed might have been 
related to reduced LV function [98]. 
In pressure overload due to AS, reactive hypertrophy will cope with the increased 
afterload until wall stress becomes so high that irreversible damage occurs [99]. Although 
most patients with advanced AS have preserved EF, myocardial dysfunction occurs through 
reactive fibrosis [100, 101]. In a previously performed study, addressing flow remodelling as 
a consequence of cellular and force remodelling occurring in ischemic heart disease, we 
have shown that decreased overall contractility results in a more symmetrical outflow velocity 
profile [52]. A study performed by Bermejo and co-workers analyzed in vivo the effects of 
flow interventions on instantaneous valvular dynamics of stenotic valves for which a custom 
algorithm for signal processing of Doppler spectrograms was developed. By plotting 
instantaneous AVA against normalized ejection time, two types of curves were obtained: 
those of rapid, early opening of the aortic valve (represented in 80% of the control group) and 
those of slow, end-systolic opening (80% of AS patients). When given a dobutamine infusion, 
the patients increased and anticipated the peak AVA, which was explained by acceleration of 
valve opening. Furthermore, the ones in which a more rapid valve opening pattern developed 
after dobutamine, demonstrated a more favourable 3-year outcome. The changes of AVA 
over time demonstrated in this study might reflect the changes in LV contractility, i.e. force 
generation and deformation of the myocardium as well. The fact that administration of 
dobutamine induced a transformation of the curve toward the early peaking type in some AS 
patients provides an additional argument to support this hypothesis [102]. Furthermore, in 
pressure overloaded rats with normal usual indices of systolic (dys)function, Derumeaux et 
al. demonstrated early abnormal LV systolic deformation. Recovery in regional deformation 
occurred after early, but not after late debanding [103]. In humans, acute improvement in 
global and regional LV systolic function was shown shortly after percutaneous AVR [100, 
103]. In a study performed in patients with AS before and promptly after balloon aortic 
valvuloplasty, Shim et al. have shown that the ejection pressure gradient and velocity traces 
tended to become less symmetric with steeper upstrokes and downstrokes, aside form the 
decrease in their values after the intervention. Furthermore, the time to peak ejection 
gradient and peak ejection velocity shortened after valvuloplasty [104].  
Using Doppler myocardial imaging, it has been shown that abnormal LV systolic function 
in AS starts at an early age of the disease with reduction of regional deformation despite 
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preserved EF [1]. In a study by Kowalski and co-authors, end-systolic strain and peak strain 
correlated with AVA, peak gradient and stroke volume [22]. Moreover, regional differences in 
deformation parameters were noted: longitudinal deformation was inhomogeneous between 
the base and apex with basal segments having significantly lower strain/strain rate values 
than apical segments. In another study, patients with severe AS showed longer time to peak 
strain and peak strain rate before AVR when compared to normal subjects, while after AVR 
these parameters tended to normalize [101]. A recent study measuring pre-and 
postoperative systolic strain-rate in patients with AS and preserved EF showed a flattened 
and delayed systolic strain-rate profile in these patients when compared to patients with 
arterial hypertension or normals, thus implying a close relation between the systolic strain 
rate curves and LV contractility [105]. 
 
In the current study we have hypothesized a relation between the instantaneous peak 
velocity profiles and impaired myocardial function in aortic stenosis which results in 
prolonged myocardial contractility, leading to a more symmetrical cardiac outflow, as 
reflected by the Doppler signal. Our data have shown that instantaneous peak velocity 
symmetry occurs in >90% of patients with severe AS before AVR and persists in only 35% of 
patients after surgery, while Doppler trace symmetry was absent from the control group 
population. By analyzing aortic CW Doppler traces we have distinguished several trace 
properties, among which the asymmetry index, showing very low values (indicative of very 
symmetric traces) within the AS preoperative group and tending to normalize during a one 
year follow-up period after aortic valve replacement. Furthermore, the preoperative traces 
were characterized by a significantly prolonged rise time and shortened fall time which both 
improved after valve replacement. Finally, the relative ejection time (ET/R-R) and relative 
time to peak (T/ET) were much longer before surgery and normalized postoperatively, 
demonstrating a prolonged ejection phase as well as its delayed peak in severe AS.  
Moreover, we have shown that the values of asymmetry before surgery are predictive of 
the change in EF pre- and postoperatively in these patients: all of the patients with markedly 
symmetric preoperative traces (asymm <0.15) showed stagnation or deterioration of EF 
postoperatively. Thus, preoperative asymmetry values ≥ 0.15 showed 95 % specificity and 
100 % sensitivity in detecting patients with an improvement in ejection fraction after aortic 
valve replacement surgery, regardless of the preoperative mean aortic gradient values. 
Furthermore, we were unable to show a correlation between classical indices of stenosis 
severity such as aortic valve area or mean aortic gradient before surgery nor preoperative EF 
and the change in EF pre- and postoperatively. When looking at a subgroup of patients with 
severe AS with a low preoperative mean aortic gradient  and low EF POST-PRE in which it is 
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usually difficult to assess AS severity and recovery according to the current guidelines, we 
have found that all of them had preoperative asymmetry <0.15.  
Moreover, preoperative asymmetry did not correlate significantly with preoperative mean 
aortic gradient, while within the subgroup of patients which showed an postoperative 
improvement in EF, a positive correlation was present between preoperative asymmetry 
values and preoperative aortic valve area (patients with lower AVA had lower asymmetry 
values – more symmetric traces). Such a correlation was not found in the patients with a 
poor postoperative EF recovery outcome. This suggests that there is a direct impact of 
stenosis severity on the instantaneous peak velocity symmetry in patients with severe AS 
without LV dysfunction, while in the ones with poor LV function trace symmetry is mostly due 
to functional impairment and myocardial damage.  
Finally, CMR data showed that signs of LE were present in half of the patients with 
preoperative asymmetry ≥ 0.15 and occurred in most of the patients with highly symmetrical 
traces (asymm < 0.15). In all patients which postoperatively retained asymm <0.25 and had 
CMR data available, evidence of LE was detected, indicating the finding of replacement 
fibrosis. This severe fibrosis affects the subendocardium, thus influencing longitudinal LV 
function which is likely to be reflected in the retained symmetry of the postoperative 
instantaneous peak velocities.   
Therefore, we can conclude that aortic Doppler trace symmetry proves to be a more 
reliable predictor of functional improvement after the valve replacement procedure as 
compared to mean aortic gradient and aortic valve area which are widely used in 
preoperative assessment of patients with aortic stenosis. 
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Chapter 6 
Detecting Volume Responders prior to Implantation of a Cardiac 
Resynchronization Therapy Device via Minithoracotomy: The Septal 
Flash as a Predictor of Immediate Left Ventricular Reverse Remodeling∗ 
 
 
6.1. Introduction 
Although cardiac resynchronization therapy (CRT) is well established as adjunctive heart 
failure treatment, a 30% rate of non-responders poses a challenge to better define the 
potential candidates before device implantation [106]. Several echocardiographic parameters 
of predicting CRT responders have been proposed, mostly based on measurements of time 
intervals between velocities of the segments of the left ventricular (LV) walls, but were shown 
to add no further benefit in predicting CRT response [44]. A mechanism based approach to 
patient selection has been recently proposed, based on multiple independent mechanisms, 
correction of which leads to CRT response [108, 109]. Along with atrioventricular and 
interventricular dyssynchrony, the septal flash has been defined as an echocardiographic 
sign of LV intraventricular dyssynchrony, occurring as a mechanical consequence of left 
bundle branch block (LBBB) induced activation of the LV. Furthermore, it has been shown 
that disappearal of the septal flash after CRT implantation, which occurred in almost 90% of 
the patients at a median follow up of 6 months, provides high sensitivity and specificity in 
detecting response to CRT.  
We hypothesized that immediate response to CRT implantation observed from the point of 
LV intraventricular dyssynchrony can be detected/predicted by resolution of the septal flash 
(immediately following device activation), thus demonstrating that the presence of a septal 
flash prior to CRT pacing is a direct consequence of early septal activation in LBBB, 
correctable by biventricular pacing.  
 
 
6.2. Methods 
6.2.1. Patients 
In this pilot study, we have studied 5 consecutive patents referred for CRT-P implantation by 
means of a left anterior mini thoracotomy. These patients underwent a preoperative 
                                                 
∗ By permission from: Čikeš M, Bijnens B, Đurić Ž, Lovrić Benčič M, Gošev I, Velagić V, Gašparović H, Miličić D, 
Biočina B. Detecting Volume Responders prior to Implantation of a Cardiac Resynchronization Therapy Device 
via Minithoracotomy: The Septal Flash as a Predictor of Immediate Left Ventricular Reverse Remodeling. Heart 
Surg Forum 2009;12(6):in press 
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echocardiography dyssynchrony screening study, as routinely performed in our centre, in 
which they were all identified as potential CRT responders based on the presence of the 
septal flash. The group consisted of 3 male and 2 female patients, mean age 62 ± 9 years. 
All patients fulfilled the current guidelines criteria for CRT implantation (EF<35%, QRS 
duration >120 ms, NYHA class III-IV, being under optimal pharmacotherapy) [110]. All 
patients underwent coronary angiography prior to CRT device implantation to exclude 
significant obstructive coronary artery disease.  
Informed, signed consent was obtained from all patients and the study was in accordance 
to the ethical guidelines of the hospital.  
 
6.2.2. Echocardiographic Imaging 
Standard cardiac ultrasound data were acquired intraoperatively pre- and post- CRT device 
implantation with a Vivid Seven ultrasound scanner equipped with a 2.5-MHz phased – array 
transducer (GE, Horten, Norway). The post-activation echocardiography sequences were 
obtained after the below mentioned atrio-ventricular (A-V) interval optimization was 
performed.   
Standard 2D data, spectral Doppler flows and myocardial velocity data were obtained 
from the parasternal and apical views. The echocardiographic data were obtained for three 
complete cardiac cycles. In patients with lower quality transthoracic views, the intraoperative 
study was extended by a transesophageal echocardiography (TEE) study (6 MHz 
transducer, GE, Horten, Norway), using the mid-esophageal and transgastric views.  
Offline analysis was performed using dedicated software (Echopac, GE, Horten, Norway). 
LV size was measured from the M-mode images [66, 67]. Left ventricular EF and LV volumes 
were measured by the Simpson biplane method from the apical 4- and 2-chamber views [66]. 
PW Doppler traces of the LV outflow acquired from the 5-chamber view were analyzed by 
planimetry of the Doppler envelope in order to obtain the stroke volume, which was 
calculated by multiplying the LV outflow tract (LVOT) velocity time integral by the LVOT area 
(the LVOT diameter was measured from the 2D image of the parasternal long axis). Cardiac 
output was further calculated as the product of the stroke volume and heart rate. Transmitral 
flow velocities were obtained by positioning the PW sample volume at the tips of the mitral 
leaflets in the 4-chamber view. dP/dt was measured from the CW traces of mitral 
regurgitation, from which the pre-systolic mitral regurgitation was assessed as well (where 
available) [44, 111].  
DMI velocity data were acquired as data superimposed on the underlying 2-D gray-scale 
image. To obtain the necessary high frame rate, the angle of insonation and depth of imaging 
were optimized, as previously described [112]. Special attention was paid to avoid aliasing 
within the image by adjusting the values of pulse repetition frequency (between 2.0-2.5 kHz).  
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The early septal fast inward/outward motion (thickening/thinning), i.e. the septal flash was 
visualized on the parasternal short or long axis views using either gray scale or tissue 
Doppler colour M-mode, where it was imaged as a rapid change of colour during the 
isovolumic contraction time (Figure 6.1, left). The amplitude of this septal motion was 
measured as the maximal excursion in the parasternal (or transgastric, in cases of TEE 
imaging) short or long axis views, or a transverse M-mode in an apical 4-chamber view. 
Furthermore, the septal flash was identified on the DMI radial velocity data as an early, fast, 
short lived negative declination shortly after the QRS onset where its peak velocity was 
measured [108, 109].  
Septal Flash
Septal Flash
Septal Flash resolution
Septal Flash resolution
 
Figure 6.1. The septal flash i.e. the early septal thickening/thinning (occurring within the 
duration of the QRS complex), visualized on the parasternal long axis view using gray scale 
(top, left) or tissue Doppler color M-mode (bottom, left), imaged as a rapid change of color 
during the isovolumic contraction time. The resolution of the septal flash as seen immediately 
after CRT device implantation (top and bottom, right). 
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6.2.3. Mini Thoracotomy and CRT Device Optimization 
The right atrial and ventricular leads were placed transvenously. The actual LV lead 
placement was performed through a left anterior mini thoracotomy, positioning the LV screw-
in lead epicardially on the LV lateral wall.  
Immediately following the CRT device activation, a simplified A-V delay screening was 
performed. In cases of a truncated or absent transmitral A wave (indicating a too short A-V 
delay) or a merged E and A wave (indicating a too long A-V delay), initial A-V optimization 
was performed using the iterative method.  
 
6.2.4. Statistical Analysis 
Continuous variables’ data are expressed as mean value ± SD. For comparative analysis, a 
paired test was performed between the pre- and post-implantation groups. Categorical 
variables are expressed as percentages. For categorical variables, comparisons between 
groups were made using the chi-square test. Results were considered significant at p<0.05.  
 
 
6.3. Results 
6.3.1. Patient Group Characteristics  
During an extensive diagnostic investigation for the aetiology of heart failure, significant 
coronary artery disease was detected by coronary angiography in only 1/5 patients, for which 
this patient underwent a percutaneous coronary intervention. Therefore, at least one year 
prior to CRT, coronary artery disease was absent/resolved in all patients. The remaining 
patients (80%) were diagnosed with idiopathic dilated cardiomyopathy. The values of neither 
systolic and diastolic blood pressure nor heart rate differed significantly before and after CRT 
device implantation (Table 6.1). All patients were in sinus rhythm before and after the 
procedure. The duration of the QRS interval decreased significantly after CRT (182±36 ms 
vs. 136±22 ms, respectively; p=0.05). The average duration of the PR interval reduced by 
biventricular pacing as well (184±43 vs. 138±17 ms, respectively; ns). 
 
6.3.2. Echocardiographic Imaging 
The obtained echocardiographic measurements are summarized in table 6.1. A significant 
reduction of LV end-diastolic dimension (7.6±1.3 cm vs. 7.2±1.2 cm, p=0.01), end-systolic 
(248±99 ml vs.180±89 ml, p=0.01) and end-diastolic volume (302±109 ml vs. 247±107 ml, 
p=0.01) were noted immediately after CRT device activation. Reverse remodelling, defined 
as a reduction of end-systolic volume (LVESV) ≥10% [113], was found in all patients (mean 
LVESV reduction after CRT activation being 27±13%, range16-46%). An immediate increase 
of EF was noted in all patients as well (mean delta EF 9±6%, range 4-19%). Furthermore, 
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dP/dt obtained noninvasively from the mitral regurgitation trace (obtainable from 4/5 patients) 
showed immediate improvement after CRT activation in all of these patients (mean delta 
dP/dt 303.2±64.2 mmHg/s, range 213-363.2 mmHg/s) (Figure 6.2). Increase in stroke 
volume and cardiac output have been noted after CRT activation, although without statistical 
significance. 3/5 patients (60%) had moderate or severe mitral regurgitation preoperatively 
which was immediately reduced with at least one grade.  
The septal flash was detected before CRT activation in all patients and has diminished 
immediately after onset of biventricular pacing with an average of 80%, measured from the 
amplitude of this early, rapid septal motion imaged by gray scale or tissue Doppler colour M-
mode, leading to normalization of septal motion (Figure 6.1). Likewise, its peak velocity 
measured from the DMI radial velocity datasets was decreased in the entire study group as 
well, with an average of 70% (Table 6.1, Figure 6.3).  
Significant interventricular dyssynchrony (expressed as a ≥40 ms delay between left and 
right ventricular pre-ejection periods measured from the aortic and pulmonary outflow 
Doppler velocity traces, respectively) was present in 60% (3/5) patients and was resolved by 
biventricular pacing in all cases.  
A significantly prolonged isovolumic contraction time (IVCT) was found before CRT device 
activation, which was significantly reduced by CRT (181±23 ms vs, 61±51 ms, respectively, 
p<0.001). The isovolumic relaxation time (IVRT) was generally shorter than the IVCT before 
pacing, by which it was somewhat prolonged, though without significance.  
Assessment of the transmitral traces before the onset of biventricular pacing showed 
absence of significant atrioventricular dyssynchrony in two patients, while a filling pattern 
correspondent to a prolonged A-V delay was revealed in two other patients (fusion of the 
transmitral E and A wave and presence of pre-systolic mitral regurgitation). This was 
resolved by CRT in one of these patients, while the other had persistent sinus tachycardia 
intraoperatively, presumably causing the ongoing E and A wave fusion after CRT activation 
(regardless of attempts to optimize the A-V delay). Finally, one patient had signs of restrictive 
filling prior to biventricular pacing which reverted to pseudonormal filling after CRT activation.   
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Pre CRT 
implantation 
Post CRT 
implantation p-value 
SBP (mmHg) 111±7 115±13 Ns 
DBP (mmHg) 67±8 66±9 Ns 
HR (/min) 67±8 74±13 Ns 
LVIDd (cm) 7.6±1.3 7.2±1.2 0.01 
LVIDs (cm) 6.6±1.4 6.2±1.1 0.05 
LVESV (ml) 248±99 180±89 0.01 
LVEDV(ml) 302±109 247±107 0.01 
EF (%) 19±5 28±5 0.01 
MR dP/dt 299±58 602±111 0.001 
Septal flash (mm) 10.2±6.9 1.5±0.7 0.02 
Septal flash (cm/s) 4.8±2.3 1.4±0.2 0.01 
IVCT (ms) 181±23 61±51 0.001 
IVRT (ms) 147±109 109±75 Ns 
IVD (ms) 60±39 29±11 Ns 
SV (ml) 59.0±6.2 66.8±14.1 Ns 
CO (ml) 4.5±0.8 4.7±1.0 Ns 
 
Table 6.1. Basic clinical and echocardiographic measurements 
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MR dP/dt  632  mmHg/s
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Figure 6.2. Significant improvement of dP/dt values derived form the mitral regurgitation 
trace (MR) before (top) and immediately after CRT device implantation, obtained by 
transesophageal echocardiography. Furthermore, pre-systolic MR present before 
biventricular pacing as a consequence of a long atrioventricular delay (top, arrow) is resolved 
by CRT (bottom). 
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Figure 6.3. The septal flash seen on the pre-implantation DMI radial velocity data as an 
early, fast, short lived negative declination shortly after the QRS onset (top) which is 
immediately resolved by CRT, normalizing the radial velocities which become mirrored 
(bottom). 
 
 
6.4. Discussion 
In this study, we have shown that patients who fulfilled guidelines criteria for CRT 
implantation, presenting with a septal flash as a marker of intraventricular dyssynchrony, 
show an acute volume response as well as contractility recruitment immediately following 
CRT device activation. 
Ventricular remodelling is in the first instance a response to either an inherent problem 
within the myocardium or the environment in which it has to work and is a compensatory 
attempt to preserve the heart’s function. In the long term, within this abnormal situation, 
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imminent mechanical disadvantages will lead to irreversible myocardial damage, leading to 
ventricular dysfunction and heart failure [71]. With new treatment concepts available for heart 
failure patients, reverse remodelling is emerging as a new entity in patients where 
progressive LV dilatation and deterioration in contractile function show partial reversibility, 
instead of stagnation [114].  
A substantial number of studies assessing survival and clinical response (change in 
NYHA class, exercise capacity and quality of life) have acknowledged the benefits of CRT, 
while the current knowledge on the mechanisms and effects of volume response is far less 
evident.  
Generally, CRT leads to a significant decrease in LV size (optimally assessed by 
measuring LV volumes), as well as an increase in LV EF [106, 115-117]. Various time 
periods have been chosen for patient follow up, at which signs of reverse remodelling have 
been documented, ranging from as early as 1 month to 18 months at which LV reverse 
remodelling and associated clinical improvement are sustained [106, 115, 116, 118]. 
Recently, long-term results from the Cardiac Resynchronization in Heart Failure (CARE-HF) 
trial have been published, reporting on the long-term effects of CRT on LV reverse 
remodelling [119]. After an average study period of 29 months after CRT implantation, it has 
been demonstrated that CRT induces sustained LV reverse remodelling, with the most 
marked effects occurring within the first 3-9 months (the earliest follow up being 3 months 
after device implantation) and further improving at following assessments.  
However, the onset of reverse remodelling induced by CRT is not well documented. In this 
study, we have demonstrated that in patients with true, LBBB induced intraventricular 
dyssynchrony (as defined by the septal flash), it occurs immediately after the activation of 
biventricular pacing. All patients within this group had preoperative evidence of the septal 
flash, deemed as a marker of intraventricular dyssynchrony, which was promptly abolished 
by biventricular pacing.  
The preoperative presence of the septal flash was appreciated as a direct mechanical 
consequence of LBBB-induced early septal activation which develops force and shortens 
against the opposite lateral wall which is still latent. Because it is contracting against a 
reduced load, it will move faster than normally, resulting in the septal flash. The septum thus 
pulls the lateral wall until the latter becomes electrically activated, at which point the lateral 
wall starts to contract and will start in turn to influence the septum, resulting in a “rocking” 
apical motion in the ejection phase [108].  
Beside a prompt, significant decrease in LV volumes and concomitant increase in EF, a 
marked increase in noninvasively obtained dP/dt was observed as well in this study, 
reflecting a direct, positive influence of CRT on LV contractility.  
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6.5. Conclusion 
In this group of patients with overt heart failure and LBBB, immediate reverse remodelling 
(volume response) to biventricular pacing occurred in all patients after CRT activation and 
appears to be a direct effect of correcting the underlying conduction abnormality and its 
mechanical consequence, which can readily be imaged by echocardiography as the septal 
flash.   
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Chapter 7 
Early Stage Acromegalic Cardiomyopathy: Evidence of LV 
Hypertrophy without Increased Afterload and Increased 
Contractility Associated with Increased Cardiac Output ∗ 
 
 
7.1. Introduction 
The excess of growth hormone (GH) occurring in acromegaly stimulates the growth of 
various tissues [120]. Cardiac myocytes carry receptors for both GH and its tissue effector, 
insulin-like growth factor-I (IGF-I) [121]. In experimental studies, it has been shown that IGF-I 
causes hypertrophy of cultured rat cardiomyocytes [122] and delays cardiac apoptosis [123]. 
In patients with acromegaly, cardiac morphology and performance are affected due to 
chronic GH and IGF-I excess which lead to a specific acromegalic cardiomyopathy [124-
126]. The first stage of acromegalic cardiomyopathy found in young patients with short 
disease duration is characterized by a hyperkinetic left ventricle (LV), increase in contractility 
and cardiac output and reduced peripheral vascular resistance [127, 128]. The second stage, 
at which the diagnosis is made in most adult patients, comprises concentric or eccentric LV 
hypertrophy, diastolic filling abnormalities at rest and impaired cardiac performance during 
physical exercise. If untreated or undiagnosed, acromegaly may lead to the final stage of 
heart involvement: valve disease and impaired systolic and diastolic function with low cardiac 
output occurring even at rest, occasionally leading to congestive heart failure [129 130]. 
Interstitial fibrosis, increased extracellular collagen deposition, myofibrillar derangement and 
areas of monocyte necrosis and lymphomononuclear infiltration, gradually impair the entire 
organ architecture as seen at histology [131]. Beside the specific cardiomyopathy, 
accompanying risk factors of acromegaly such as arterial hypertension, dyslipoproteinaemia, 
diabetes mellitus and peripheral insulin resistance [132, 133], lead to the fact that 
cardiovascular abnormalities are among the major causes of increased morbidity and 
mortality rates in acromegaly [134, 135].  
Blood pool Doppler echocardiography provides a method to measure the blood velocities 
within the ventricles and blood vessels [51]. By measuring velocities through the cardiac 
valves, the amount of flow (cardiac output, filling) and the driving pressure gradient, causing 
                                                 
∗ From: Cikes M, Separovic Hanzevacki J, Kastelan D, Dusek T, Lovric Bencic M, Ernst A, Korsic M, Bijnens B. 
Early Stage Acromegalic Cardiomyopathy: Evidence of Left Ventricular Hypertrophy without Increased Afterload 
and Increased Contractility Associated with Increased Cardiac Output. Submitted for review. 
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the flow, can be quantified [51, 53-60], which can be clinically used to assess hemodynamic 
parameters and ventricular function [51, 53-57].  
The profile of the aortic flow velocity curves can be described by the rate of increase 
(acceleration) in velocity, the peak and the time of peak velocity, the mean velocity during 
systole and the ejection duration [51]. Normal outflow shows an asymmetric, triangular 
shaped profile with a fast rise in velocities and peaking around 1/3 of the ejection duration 
[51]. Animal studies have shown that the flow acceleration is a sensitive indicator of the 
inotropic state [61], which was confirmed by clinical research [56, 62]. In LV failure, both a 
lower and a slower increase in velocities (a more rounded Doppler profile with a later peak 
velocity) were observed [51].  
The most common feature of early stage acromegalic cardiomyopathy is biventricular 
hypertrophy which is initiated in the absence of any increase in wall stress [136]. 
Consequently, unlike in other forms of hypertrophy, wall stress may be reduced [137]. We 
hypothesize that the visually hyperkinetic LV which occurs in the earlier stages of disease is 
associated with Doppler signs of increased contractility in acromegaly patients, while 
commonly used indices of systolic function such as EF still remain unchanged.  
Additionally, an increase in aortic root diameter has previously been demonstrated in 
patients with acromegaly [138], which was shown not to be related to increased afterload. 
However, this finding has not been related to an increase in LV contractility,  
 
 
7.2. Methods 
7.2.1. Patients 
37 patients with acromegaly (20 female, 17 male, mean age 50.1 ± 10.5 years) were 
included to this study. The diagnosis of acromegaly was based on specific clinical 
characteristics, failure to suppress serum GH level bellow 2 mIU/L after a glucose tolerance 
test and a high serum IGF1 level for age. The patients who were successfully treated by 
pituitary tumor surgery, had normal IGF-1 level for age and adequate suppression of GH 
after glucose load were considered to be in disease remission. The disease duration was 
defined as the time interval between the clinical onset of disease (based on patient history 
and comparison of old photographs) and the echocardiographic exam date (in the active 
acromegaly subgroup), or the interval between clinical onset and successful pituitary tumor 
surgery (in the remission group). Patients were divided into two subgroups based on disease 
activity. 25 patients (13 female, 12 male, mean age 52.4±10.9 years) had active disease, i.e. 
they were included in the study before any therapeutic regimen was applied. Other 12 
patients (7 female, 5 male, mean age 45.3±8.3 years) were included in the study after the 
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successful neurosurgical treatment and were considered to be in disease remission. Mean 
disease duration was 6.6 ± 6.0 years. 
The acromegalic patients were compared to 15 patients with arterial hypertension (7 
female, 8 male, 52.7±16.6 years, normal EF), which was defined as blood pressure > 140/90 
mmHg [139].  
32 healthy volunteers (15 female, 17 male, mean age 44.9 ± 15.2 years) with no signs or 
symptoms of arterial hypertension, diabetes mellitus or heart disease served as a control 
group.  
 
7.2.2. Echocardiographic Imaging 
All participants underwent a complete standard echocardiographic study (2D, M-mode, 
pulsed, and continuous Doppler). During the examination, the participants were lying in the 
left lateral decubitus position. The echocardiographic data for three complete cardiac cycles 
during a single end-expiratory breath holding were acquired with a Vivid Seven ultrasound 
scanner equipped with a 2.5-MHz transducer (GE, Horten, Norway). Data were obtained 
from the parasternal and apical views. For the 2D studies, parasternal long and short axis as 
well as apical two-, three-, four- and five-chamber views were used. Aortic outflow 
continuous (CW) and pulsed (PW) wave Doppler traces were acquired from the apical five-
chamber view. The echocardiographic data were obtained for three complete cardiac cycles 
during a single end-expiratory breath hold. Offline analysis was performed using dedicated 
software (Echopac, GE, Horten, Norway). EF was measured by the Simpson biplane method 
[66]. LV size and mass (LVM) were measured [66] and indexed to body surface area in order 
to obtain the LV mass index (LVMI) [18]. The aortic root diameters were measured by M-
mode, guided by a parasternal long axis image. The velocity time integral (VTI) was 
measured by tracing the signal of transaortic flow from pulsed-wave Doppler traces. Ejection 
time (ET) was measured as the time difference between the clicks of aortic valve opening 
and closure detected from pulsed-wave Doppler traces of the transaortic flow. ET was 
indexed by heart cycle duration (R-R) to obtain relative ET duration (ET/R-R). LV stroke 
volume (SV) and cardiac output (CO) were calculated pertaining to previously described 
formulae [54].  
The study was performed according to the regulations of the Ethics Committee of the 
Zagreb University Hospital Centre and informed consent was obtained from all volunteers 
and patients. 
 
7.2.3. Hormone Essays 
Serum IGF-1 was measured by enzyme-linked immunosorbent assay (ELISA; Biocode-
Hycel, Belgium) and GH level was assayed by radioimmunoassay (RIA; IBL Germany).  
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7.2.4. Statistical Analysis 
Continuous variables’ data are expressed as mean value ± SD and the unpaired two-tailed 
Student t-test was performed for comparative analysis. Categorical variables are expressed 
as a percentage. For categorical variables, comparisons between groups were made using 
the chi-square test. Results were considered significant at P<0.05. 
 
 
7.3. Results 
7.3.1. Patient Group Characteristics 
The clinical characteristics of the studied patients and the control group are provided in Table 
7.1. None of the three study groups differed significantly in age. Interestingly, the BSA did not 
differ significantly between the hypertensive and acromegalic patients, mostly due to 
concomitant adiposity of the hypertensive patients. The values of systolic (SBP) and diastolic 
blood pressure (DBP) were significantly higher in the hypertension group than the other two 
groups, while SBP and DBP were significantly higher in the acromegaly group compared to 
the control group. Arterial hypertension was present in 40% of the acromegalic patients. The 
serum levels of GH and IGF-I were, as expected, significantly higher in patients with active 
disease, when compared to those in remission (Table 7.3). 
 
 
Control 
(n=32) 
Hypertension 
(n=15) 
Acromegaly 
(n=37) 
Age (years) 44.9±15.2 52.7±16.6 50.1±10.5 
gender (male/female) 15/17 8/7 17/20 
BSA (m2) 1.87±0.22 2.00±0.15* 2.01±0.26* 
Acromegaly duration (years) - - 6.5±6.0 
Remission (%/no) - - 68/25 
Active disease (%/no) - - 32/12 
Systolic BP (mmHg) 121.0±9.2 159.5±16.7† 134.6±19.4†‡ 
Diastolic BP (mmHg) 71.0±5.5 100.0±10.0† 84.6±9.4†‡ 
heart rate (bpm) 73.0±11.6 72.1±7.4 74.2±11.2 
Hypertension (%/no) - 100/15 40/15 
Table 7.1. Clinical Patient Characteristics 
* P<0.05 vs. control; †P<0.0005 vs. control, ‡ P<0.002 vs. hypertension. 
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7.3.2. Basic Echocardiography Data and Doppler Outflow Analysis  
Echocardiographic measurements revealed that the group of acromegalic patients had the 
largest LV with the highest LVM (P<0.005 vs. control) (Table 7.2). Notably, the size of the 
aortic root was the largest in the acromegaly group, followed by the group of hypertensive 
patients (P<0.005 acromegaly vs. control, P<0.05 hypertension vs. control). The ET and 
ET/R-R were the shortest in the acromegaly group (P<0.05 vs. control, P<0.005 vs. 
hypertension and P<0.05 vs. control, P<0.05 vs. hypertension, respectively), while these time 
intervals were the longest in the group of patients with hypertension (Figure 7.1.). Inversely, 
T/ET was the longest in acromegalic patients (P<0.05 vs. control and HTN), while it was the 
shortest in the control group. Furthermore, SV and CO had by far the largest values in the 
acromegaly group (P<10-6 vs. control, P<20-6 vs. hypertension). No significant difference was 
noted among the three groups in respect to EF (Table 7.2). 
 
 Control (n=32) Hypertension (n=15) Acromegaly (n=37) 
LVIDd (cm) 4.97±0.41 5.07±0.42 5.35±0.51* 
IVS (cm) 0.93±0.15 1.06±0.15 1.05±0.21† 
LVPW (cm) 0.87±0.17 0.99±0.19 0.97±0.14† 
LVM ASE (g) 143.2±29.1 179.1±22.1* 189.8±51.3* 
LVMI (g/m2) 76.5±11.9 93.1±13.1* 94.5±24.2* 
EF (%) 67.1±7.5 68.3±9.9 65.7±10.1 
ET (ms) 284.7±23.3 300.1±26.5 267.4±27.3†‡ 
ET/R-R 0.34±0.04 0.36±0.03 0.33±0.03†§ 
T/ET 0.22±0.04 0.24±0.05 0.25±0.05†§ 
AV SV (mL) 84.1±20.4 87.3±16.0 158.3±60.1║¶ 
AV CO (L/min) 6.0±1.3 6.0±1.0 11.8±4.5║¶ 
 
Table 7.2. Echocardiography Measurements 
* P<0.005 vs. control; †P<0.05 vs. control, ‡ P<0.005 vs. hypertension, § P<0.05 vs. 
hypertension, ║P<0.000001 vs. control, ¶ P<0.000002 vs. hypertension 
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Figure 7.1. Values of ET and ET/R-R among the three patient groups. 
 
7.3.3. Acromegaly Patient Subgroups and Echocardiography Measurements 
Within the acromegaly group, the patients with active disease were the eldest, had the 
longest disease duration and the highest SBP values (P<0.03 vs. remission) (Table 7.3.). 
Furthermore, the group of patients with active disease had the highest LV mass, EF, VTI, SV 
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and CO, longest T/ET and shortest ET, although all non-significant. Notably, ET/R-R was the 
shortest in this group (P<0.03 vs. remission). 
Although the patients with acromegaly had significantly higher BP values than the control 
group, they showed no significant correlation between LVMI and SBP values (r=0.43) (Figure 
7.2.). Within the control group, no significant correlation was found between LVMI and ET/R-
R nor LVMI and VTI (r=0.13 and r=0.37, respectively) (Figure 7.3. left). A significant 
correlation was absent between these parameters within the arterial hypertension group as 
well (r=0.15 for both correlations). Conversely, the acromegalic patients presented a negative 
correlation between LVMI and ET/R-R (r=0.34) and a positive correlation between LVMI and 
VTI (r=0.58) (Figure 7.3. right).  
 
Remission (n=12) 
Active disease 
(n=25) 
Acromegaly all 
(n=37) 
Age (years) 45.3±8.3 52.4±10.9* 50.1±10.5 
gender (male/female) 5/7 13/12 17/20 
Disease duration (years) 3.5±2.8 8.0±6.6* 6.5±6.0* 
GH (mIU/L) 1.7±3.0 27.5±46.5* 18.4±39.2* 
IGF-I (nmol/L) 41.3±20.2 108.5±41.9† 86.1±48.1† 
EF (%) 63.3±8.3 66.9±10.9 65.7±10.1 
SBP (mmHg) 126.0±10.5 138.1±21.1* 134.6±19.4 
LVM ASE (g) 176.8±72.4 196.6±36,1 189.8±51.3 
LVMI (g/m2) 87.9±28.2 97.9±21.6 94.5±24.2 
LVH (pts/%) 2/17 4/16 6/16 
ET (ms) 273,4±28.2 264,1±26,9 267.4±27.3 
ET/R-R 0.34±0.03 0.32±0.03* 0.33±0.03 
T/ET 0.24±0.06 0.26±0.05 0.25±0.05 
AV VTI (cm) 21.8±4.5 24.8±5.0 23.8±5.0 
AV SV (mL) 150.7±51.2 162.5±65.5 158.3±60.1 
AV CO (L/min) 10.7±4.3 12.4±4.6 11.8±4.5 
 
Table 7.3. Acromegaly Patient Characteristics and Echocardiography Measurements 
* P<0.03 vs. remission, † P<0.00005 vs. remission 
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Figure 7.2. The correlation between SBP and LVMI in acromegaly patients. 
 
 
 
Figure 7.3. The correlation between ET/RR and VTI vs. LVMI in the control group (left) and 
acromegaly patients (right). 
 
 91
7.4. Discussion 
In this study we have demonstrated that the visually hyperkinetic LV with normal EF, before 
the onset of functional impairment, is associated with Doppler signs of increased contractility 
in acromegalic patients. The values of stroke volume and cardiac output are substantially 
greater than in patients with hypertension or the control group, while a significantly shorter 
ET/R-R in acromegalic patients implies increased LV contractility, leading to a more rapid 
outflow phase. Notably, the values of EF did not differ between the three groups. In 
acromegalics, a shorter ET/R-R as well as an increased VTI (indicating increased outflow) 
correlated with an increase in LV mass.   
An increase in the ejection phase indices has been demonstrated in normal subjects after 
short term GH administration [140]. Previous research has shown that IGF-I increases the 
intracellular calcium content and enhances the calcium sensitivity of myocyte myofilaments 
[141], which is found to be the most likely mechanism of increased myocardial contractility in 
animal models of chronic GH excess [32, 129]. Furthermore, it is known that active force 
development in the myocytes peaks around 1/3 of the ejection, after which it decreases 
rapidly [52]. This implies that the early LV outflow acceleration is caused by active myocyte 
contraction, while flow decelerates when force development declines, explaining why flow 
acceleration increases with increased contractility. Sabbah et al. have demonstrated that the 
peak acceleration of aortic blood flow assessed non-invasively with a CW Doppler velocity 
meter is a useful indicator of global LV performance [62], thus confirming data from 
experimental setups as well [61]. Hatle et al showed that the relative timing of the maximal 
aortic flow occurred later in LV heart failure, while the lowest values of time to peak velocity 
were found in patients with hyperkinetic heart syndrome or with considerable aortic 
regurgitation [59]. In a previous study, we have observed that the aortic outflow velocity 
profile is altered in the presence of coronary artery disease in which the flow profile becomes 
more symmetrical and rounded with a delayed time to peak velocity, whereas it is 
asymmetrical and triangular in normal subjects [142]. Additionally, a very asymmetrical and 
early peaking profile implied increased contractility in patients prone to the development of a 
dynamic intracavitary gradient during dobutamine stress echocardiography. 
While diastolic dysfunction may be present in early acromegalic cardiomyopathy, normal 
parameters of systolic function at rest have been previously described in patients early after 
onset of disease [143]. Nevertheless, radionuclide studies have demonstrated an impairment 
of EF on effort, revealing functional alterations in the majority of the studied patients, 
although more pronounced in higher patient age and longer disease duration [144]. 
Although 40% of our patients with acromegaly had concomitant hypertension, their BP 
values were significantly lower than within the arterial hypertension group. Moreover, a 
significant correlation was not found between the values of SBP and LVMI within the 
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acromegaly group, allowing us to consider that LVH in these patients is not a consequence 
of pressure overload remodelling. Additionally, an increase in pressure overload due to 
hypertension would lead to prolonged ET/R-R which is obviously not the case in our 
acromegaly group. Nevertheless, Fazio et al. have shown that systemic vascular resistance 
is reduced in acromegaly patients [136], which might additionally contribute to the shortened 
ET/R-R interval in these patients. 
In this study, the values of LV mass were significantly higher within the acromegaly and 
hypertension patient groups than in the control group, while they were comparable among 
the first two groups. Nevertheless, the underlying mechanism of hypertrophic remodelling 
differs in acromegaly and hypertensive heart disease. Remodelling is in the first instance a 
response to a problem with either the muscle itself or the environment in which it has to work 
and is an attempt to keep on fulfilling the heart's task - circulating the blood [145]. 
Hypertrophic remodelling in hypertension is an adaptive process to an increase in wall stress 
occurring in pressure overload [9]. Wall stress is directly related to the intracavity pressure 
and the radius of curvature of the ventricle while it is inversely related to wall thickness. 
Therefore, as a response to increased wall stress, an increase in wall thickness i.e. 
ventricular hypertrophy will be induced, being an adaptive process which leads to a reduction 
of wall stress. Conversely, early stage acromegalic cardiomyopathy comprises biventricular 
hypertrophy, which is, unlike hypertensive heart disease, initiated in the absence of an 
increase in wall stress [136] and is predominantly induced by the direct effects of chronic GH 
and IGF-I excess, inducing myocyte hypertrophy.  
Although the values of LVMI were significantly higher in our group of acromegalic patients 
compared to the control group, only mild, initial LVH was present in most of our patients. 
Compared to data from Fazio et al. studying a group of young patients with short term (<5 
years) acromegaly [146], although older in age and with longer disease duration, our group 
of patients had lower values of LVMI and signs of (supra)normal systolic function, thus being 
representative of early stage acromegaly. 
The stroke volume and cardiac output were significantly increased in the acromegaly 
group, in the absence of any valve regurgitation, shunt or anemia. Although GH has been 
shown to induce sodium retention and volume expansion [147-149], which might additionally 
explain the increased LVIDd measurements in the context of volume overload, the only 
explanation for the increased SV is the increase in contractility due the hypertrophy in the 
absence of increased pressure loading. The increase in volume flow in the aorta results in an 
increase in wall shear stress, which in itself will induce vessel dilatation [150]. This can 
explain the observed increase in the aortic root size. 
Thus, the increase in aortic root diameter in acromegaly is likely to be secondary to the 
increase in contractility and SV occurring in the early course of the disease.  
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Unlike other forms of hypertrophic remodelling which often lead to early signs of 
myocardial fibrosis detectable by late gadolinium enhancement imaging, CMR performed in 
patients with acromegaly has not shown signs of myocardial fibrosis [151]. Therefore, before 
the onset of disease progression and development of heart failure, acromegalic 
cardiomyopathy may be considered as a model for LV hypertrophy and increased 
contractility without an alteration in loading conditions.  
 
 
7.5. Conclusion 
A significantly higher degree of LVH in patients with acromegaly compared to normals and 
hypertensive patients is associated with a shorter ET/R-R suggesting the presence of 
increased contractility in the acromegalic hearts, resulting in an increase in outflow, both of 
which are not induced by changes in loading. Additionally, the aortic diameter is increased, 
most likely due to the increased wall shear stress induced by the volume increase. Thus 
acromegalic heart disease, at an early stage, shows evidence of hypertrophy and 
hypercontractility without an additional change in afterload resulting in increased cardiac 
output and inducing additional signs of vascular remodelling.   
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Chapter 8 
The New Role of Echocardiography in the Diagnosis and 
Assessment of Hypertrophic Myopathies ∗ 
   
 
8.1. Introduction 
Echocardiography plays a leading role in the assessment and diagnosis of hypertrophic 
ventricles in daily clinical practice. However, since the current clinical assessment of the 
hypertrophically remodelled myocardium is mostly performed using M-mode based 
geometric measurements and global measurements of left ventricular function, it is 
traditionally assumed that diastolic properties are primarily impaired, while systolic function is 
preserved until late in the course of the disease. Furthermore, as opposed to ischaemic heart 
disease, hypertrophic myopathies are considered to globally affect the myocardium.  
Unlike physiologic hypertrophic remodelling which may be seen in athletes, examples of 
cardiac conditions leading to myocardial hypertrophy are: 
• Reactive hypertrophy due to pressure overload in hypertension or aortic stenosis: 
hypertrophy will compensate the increase in afterload until high values of wall stress 
induce irreversible damage.  
• Hypertrophic cardiomyopathy (HCM), amyloidosis, Fabry’s disease, Friedreich’s 
ataxia: if undiagnosed and untreated, the final stage of heart involvement results in 
impaired systolic and diastolic function with low cardiac output leading to congestive 
heart failure.  
In all of these diseases, a better insight in the pathways of adaptive changes in cardiac 
function together with better and more specific evaluation, might help to improve patient 
management, where for the long-term prognosis, it would seem preferable to prevent the 
occurrence of myocardial fibrosis and irreversible myocyte degeneration, prevent 
arrhythmias and optimise diastolic function. Thus, it is of high clinical importance to detect 
and treat myocardial dysfunction at an early stage, preferably prior to the onset of irreversible 
myocite injury.  
Recent advances in echocardiography have provided insight in regional myocardial 
motion and deformation. Ultrasound deformation imaging (through Doppler myocardial 
imaging (DMI) or speckle tracking) provides more sensitive markers of early myocardial 
dysfunction, compared to standard echocardiographic parameters [1]. Both basic and clinical 
                                                 
∗ From: Cikes M, Bijnens B, Anderson L, Sutherland G. The New Role of Echocardiography in the Diagnosis and 
Assessment of Hypertrophic Myopathies. Submitted for review.  
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research, applying deformation analysis tools, has put a focus on the regional level in 
hypertrophic ventricles, revealing early, often subclinical impairment in systolic (longitudinal) 
function and providing better insight to understanding the pathophysiological mechanisms 
underlying the progression of disease. From this, it has become clear that each of the 
different etiologies leading to (regional) hypertrophy have a specific signature in regional 
changes in deformation. Therefore, these specific markers can be used to discriminate the 
hypertrophic processes and to improve the assessment and follow-up of treatment. 
 
 
8.2. Ventricular Remodelling  
Ventricular remodelling is a mechanism by which the ventricle reacts and tries to adapt to a 
problem, either intrinsic to the myocardium or related to the environment it has to interact 
with, intended to generate an adequate cardiac output as required by the peripheral organs 
(figure 8.1.). However, such an adaptation implies inherent disadvantages and may induce 
irreversible myocardial damage, potentially evolving into cardiac dysfunction and heart 
failure.  
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Figure 8.1. Balance of cardiac contractility and loading. 
 
Remodelling is triggered by the average local myocardial wall stress. Wall stress is 
dependent on the ventricular pressure, which is transferred to the myocardium depending on 
the local geometry (radius of curvature and wall thickness) (figure 8.2.). Grossman et al. 
have suggested that increased peak systolic wall stress (as seen in pressure overload) 
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stimulates the formation of hypertrophy by parallel replication of contractile material within 
the myocyte (figure 8.3.) [33, 152]. Conversely, the trigger for ventricular dilatation is the 
increase in end-diastolic wall stress (typically seen in volume overload), releasing factors 
within the myocardium that will stimulate the serial lengthening/replication of the sarcomeres, 
effectively resulting in the enlargement of the cavity. However, it has to be kept in mind that 
dilatation itself will change the geometry of the cavity and by increasing the local radius of 
curvature will increase wall stress (and potentially trigger the development of local 
hypertrophy, as well).  
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Figure 8.2. Myocardial wall stress and its determining factors. 
 
Most non-ischemic remodelling, like left ventricular hypertrophy (LVH), has classically 
been considered as a substrate affecting the ventricle globally. However, it has been shown 
that e.g. arterial hypertension results in localized LVH [9] due to regional differences in wall 
stress, suggesting that regional phenomena might play a more important role than previously 
assumed in clinical practice. This implies that enhanced understanding of LV remodelling 
might still lead to improved treatment of these patients.  
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Figure 8.3. A. Mechanisms for ventricular remodelling (adapted from [33]). 
B. Pressure versus volume overload. 
 
For the clinical evaluation of patients with signs of ventricular remodelling, a good method 
which can evaluate and track the evolution of intrinsic cardiac function is necessary. 
However, this is influenced by abnormal loading conditions and altered ventricular geometry, 
which can be found in several of these heart diseases, importantly affecting the current 
methods used to evaluate cardiac function.  
 
 
8.3. Normal Myocardial Motion and Deformation 
Two-dimensional (2D) echocardiography allows the assessment of the heart’s geometry and 
the presence of ventricular hypertrophy by quantifying cavity sizes, wall thickness and 
calculating the myocardial mass (index) [18], while Doppler echocardiography provides direct 
insight to cardiac haemodynamics. In the evaluation of (systolic) myocardial function, the 
intrinsic fibre and myocyte properties are of utmost importance, since they determine 
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whether a chronic condition has affected the myocardium and thus when irreversible injury 
has been induced. Currently, in everyday clinical practice, only indirect measurements of 
contractility and volume ejection are being used, mainly derived from non-invasive cardiac 
imaging techniques such as echocardiography, computed tomography (CT) and cardiac 
magnetic resonance imaging (CMR), using indices as ejection fraction (EF) or fractional 
shortening. These volume-derived parameters are associated with significant limitations in 
the event of altered loading conditions: (I) the evaluation of intrinsic myocardial function 
based on volume-derived indices, i.e. EF or fractional shortening, relies on geometric 
assumptions. The influence of ventricular shape and wall thickness on these indices is not 
well known. In hypertrophic ventricles, ‘supranormal’ values of EF are frequently measured - 
it is not well known whether these values are reflective of true contractility changes [17]. (II) 
Another limitation of all volume derived indices is important load dependency. During the 
progression of the disease, alterations in loading conditions or geometry will influence the 
(global) functional evaluation. (III) Furthermore, conventional imaging indices assess only 
global cardiac function while the evaluation of regional cardiac function is relevant in most 
conditions affecting myocardial contractility. Moreover, some of the methods evaluating 
global function focus entirely on radial indices, omitting longitudinal function that is affected 
prior to the changes in radial function in most cases of cardiac pathology [19]. An increase in 
radial function often compensates for the impairment of global longitudinal function. (IV) 
Finally, measurements of global function do not consider segment interactions which may 
only result in regional wall deformation, not contributing to pressure increase or a reduction in 
overall ventricular volume to contribute to stroke volume [20, 145]. 
In the context of these limitations, new echocardiographic methods focusing on regional 
ventricular function have been proposed. Doppler myocardial imaging (also known as 
Myocardial Velocity Imaging or Tissue Doppler Imaging) as well as greyscale (2D) speckle 
tracking are recent echocardiographic techniques that allow to quantify myocardial 
segmental motion [1]. Post-processing of velocity data or image-processing of greyscale 
data, allow the calculation of regional myocardial deformation. Myocardial deformation can 
be quantified by strain rate or the speed of deformation, as well as by strain or the amount of 
deformation. When using myocardial velocities, strain rate is calculated as the spatial 
derivative of local (neighbouring segment) myocardial velocities, while strain is derived as a 
temporal integral of strain rate. Tracking the motion of the speckle patterns of greyscale 
images provides potentially similar information. Unlike a normal base-apex gradient occurring 
in myocardial velocities (with the highest velocities at the base of the heart), a relatively 
homogenous distribution of peak systolic strain(-rate) values appears within the LV walls, 
Furthermore, the main limitation of velocity data is the influence of myocardial segment 
interaction (tethering of adjacent segments) and overall heart motion. This limitation has 
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been resolved by deformation imaging, as it measures local changes of deformation within a 
myocardial segment and should thus better reflect intrinsic contractile function [1].  
The longitudinal motion/deformation (describing the basal LV displacement towards a 
stationary apex) can be evaluated from an apical view. From a parasternal (short- and/or 
long-axis) view, the inward radial deformation (best with Doppler based techniques) as well 
as the circumferential shortening (best with speckle tracking approaches) can be measured 
[145]. 
The deformation of a myocardial region throughout the cardiac cycle [10] (Figure 4 A) 
consists of normal deformation (i.e. longitudinal lengthening/shortening, radial 
thinning/thickening as well as circumferential lengthening/shortening) and shear (i.e. base-
apex twist, epi-endocardial circumferential shear and epi-endocardial longitudinal shear) [1, 
25, 26].  
Figure 8.4. B shows a typical longitudinal deformation (strain) and speed of deformation 
(strain-rate) trace from a normal adult (obtained by high frame-rate DMI). Deformation is 
relatively homogenous in the normal myocardial wall while its patterns will be distorted in 
different cardiac pathologies. When applying Doppler based approaches, radial and 
longitudinal motion and deformation are mostly studied, since circumferential motion is 
difficult to align with the ultrasound beam, which is required by this method. It has been 
shown that speckle tracking is more reproducible and is less dependent on user expertise, 
while it inherently requires more temporal and spatial averaging of the obtained traces, which 
results in significantly lower measured values than DMI and less sensitivity to detect smaller 
abnormal myocardial segments [28, 30, 31, 145]. 
 
 
 
Figure 8.4. A. Normal myocardial motion and deformation and its three major 
components: longitudinal, radial and circumferential motion/deformation;  
B. Typical profiles of strain-rate and strain traces (adapted from [145]).  
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8.4. The Athlete’s Heart  
The “athlete’s heart” is a form of physiologic hypertrophic remodelling which may occur as a 
consequence of long-term exercise training [153]. Magnetic resonance spectroscopy studies 
have supported that ventricular hypertrophy in athletes is associated with a normal cardiac 
energy metabolism, both at rest and during atropine-dobutamine stress [154, 155]. However, 
long term LV adaptation in very high-level endurance athletes may also lead to LV cavity 
dilatation [156]. Morganroth et al. were the first to demonstrate that different hypertrophic 
remodelling patterns are associated with two basic training substrates: isotonic exercise 
(such as swimming or running) leads to an increase in LV mass and mean LV end-diastolic 
volumes, similar to chronic volume overload, while isometric exercise (wrestling, shot putting) 
induces an increase in LV mass as well, although with normal values of mean LV end-
diastolic volumes, mimicking chronic pressure overload, which was supported by further 
research [157, 158]. Similarly to humans, exercise induced remodelling has been described 
in animals as well [159]. As opposed to pathological LVH, which is characterized by 
structural changes and collagen accumulation along with myocyte hypertrophy, physiological 
LVH results in an increase in ventricular mass with underlying normal cardiac structural 
organization and no collagen increase [103, 160, 161]. In an animal study performed by 
Derumeaux et al. it has been demonstrated that both exercise and aortic banding lead to 
similar and significant LVH. Nevertheless, systolic and diastolic myocardial velocity gradients 
(i.e. strain-rates) were similar in sedentary and exercising rats (indicating that exercise leads 
to physiologic hypertrophy, not influencing myocardial function), while the gradients were 
significantly reduced in rats with aortic banding (pathologic hypertrophy occurring due to an 
increase in afterload, reducing systolic function) [103].   
In a study comparing patients with HCM, systemic hypertension and athletes, Vinereanu 
et al. have demonstrated a decrease in long-axis systolic and early diastolic velocities in 
patients with pathologic hypertrophy, while these parameters were preserved in athletes. 
[10].  
It has also been shown that athletes with LVH have enhanced global and long-axis 
diastolic function, compared to sedentary normals [10, 162]. Another study of athletes’ 
regional myocardial function has shown higher systolic and diastolic velocities in several LV 
regions, while deformation parameters (strain and strain rate) showed normal values of these 
parameters in athletes when compared to the control group, although with a tendency to 
somewhat higher mean values [163]. Myocardial deformation studied in athletes with LVH 
demonstrated an overall normal myocardial deformation [164]. Finally, a “supranormal” LV 
velocity pattern (including both systole and diastole), as well as “supranormal” values of 
systolic strain rate have been described in several studies on athletes with LVH [165-167]. 
This was supported by 2D strain data demonstrating higher values of transverse and radial 
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strains in athletes (compared to patients with HCM and normals), while in pathologically 
hypertrophic segments longitudinal strain was lower in patients with HCM than in athletes 
[168].  
 
 
8.5. Pressure Overload (Hypertensive Heart Disease and Aortic Stenosis) 
Typical examples of hypertrophic remodelling induced by pressure overload are hypertensive 
heart disease and aortic stenosis. Hypertensive LVH is characterized by increased LV mass 
and relative wall thickness [68] and may be associated with reduced global systolic function, 
due to longstanding pressure overload. Nevertheless, due to increased radial systolic 
performance associated with hypertrophy, standard indices of global systolic function such 
as EF and short axis endocardial shortening may be supranormal in early stages of the 
disease [19, 169, 170]. Beside increased radial systolic function, an increase in 
circumferential systolic function and systolic torsion, measured by 2D speckle tracking 
echocardiography, were demonstrated in hypertensive patients [171, 172], while the LV 
radial and circumferential systolic impairment appears in patients with heart failure symptoms 
NYHA III and IV class [173]. Conversely, reduced longitudinal systolic function has been well 
documented at early stages in patients with hypertension, both by conventional 
echocardiography, velocity and deformation imaging, as well as CMR tagging [9, 10, 174]. 
Although hypertensive left ventricular hypertrophy is mostly considered to be a global 
myocardial disease, resulting in concentric (symmetrical) LVH and overall reduction of 
deformation parameters, it has been shown that the distribution of LV wall stress on different 
LV segments is not homogenous, being significantly greater upon the septal wall [175]. 
Further studies have shown that the basal septal segment, being under increased wall stress 
associated with a greater local radius of curvature, is the first to show changes under the 
influence of pressure overload: both a decrease in deformation parameters (strain, strain-
rate) as well as the development of post-systolic deformation and localized hypertrophy 
occur (figure 8.5.) [9, 176]. The initiation and localization of functional abnormalities in the 
basal septum has been confirmed by 2D speckle tracking as well [172]. With increasing 
overload, the entire ventricle becomes hypertrophic and shows less deformation.  
Strotmann et al. have compared patients with preserved EF and the same extent of LVH 
induced by arterial hypertension or aortic stenosis [105]. Generally, the systolic segment of 
the strain-rate profile was more flattened in patients with aortic stenosis. Radial and 
longitudinal systolic strain rates were depressed in patients with aortic stenosis, compared 
with those with arterial hypertension and controls. This was contributed to higher wall stress 
due to higher LV end-systolic pressures as well as a higher amount of perimyocytic fibrosis, 
which was previously demonstrated in patients with aortic stenosis, compared to those with 
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hypertension [177].  Furthermore, regional differences in deformation parameters were noted 
in a study on patients with aortic stenosis by Kowalski et al: longitudinal deformation was 
inhomogeneous between the base and apex, with basal segments having significantly lower 
strain/strain rate values than apical segments [22]. A prospective follow-up study by 
Weidemann et al, investigating the effect of myocardial fibrosis on myocardial performance in 
symptomatic severe aortic stenosis, demonstrated the development of myocardial fibrosis, 
typically located subendocardially at the basal segments of the LV. This type of fibrosis, 
demonstrated by CMR LE, was found to have a profound impact on long-term clinical 
outcome in these patients. Nevertheless, such fibrosis remains undetected by standard 
echocardiography until the terminal disease stages, but its functional consequences can be 
detected by longitudinal mitral ring displacement which predicts functional improvement after 
valve repair [178].These findings suggest that remodelling in aortic stenosis may be seen as 
a continuation of the adaptation to pressure overload (systolic wall stress), underlying 
regional remodelling in hypertension.  
A discrimination between hypertensive LVH and non-obstructive HCM has been 
suggested by Kato et al, based on the septum/posterior wall thickness ratio and averaged 
longitudinal systolic strain values of eight myocardial segments [179]. A systolic strain cutoff 
value of -10.6% discriminated between HCM and hypertensive LVH with a sensitivity of 85%, 
specificity of 100% and predictive accuracy of 91.2%, with lower values in the HCM group of 
patients. This is supported by the finding that, while decreased deformation is present in the 
basal septum in hypertensive heart disease, it is never as low as showing almost absence of 
deformation, as observed in HCM [176]. Thus, an average value of systolic strain in several 
myocardial segments will be lower in HCM. Therefore, basal septal deformation is the most 
sensitive to changes in pressure overload pathology, emphasizing the regional nature of 
initial remodelling. Finally, with increasing overload, hypertrophy is induced over the entire 
ventricle, but reactive hypertrophy will cope with the increased afterload until wall stress 
becomes so high that irreversible damage (fibrosis) occurs [99].  
 
 
8.6. Hypertrophic Cardiomyopathy   
Hypertrophic cardiomyopathy is a disease with autosomal dominant transmission, caused by 
mutations in the genes encoding protein components of the cardiac sarcomere, occurring in 
1:500 of the general population [180-182]. Due to the fact that the defective genes encode 
contractile proteins such as myosin - binding protein C, β – myosin heavy chain, Troponin T 
and I, it leads to a disorder of force generation within the myocardium [180].  
In the recent years, molecular genetic and clinical research have demonstrated that there 
is not a minimum LV wall thickness required to be compatible with the presence of one of the 
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HCM mutant genes [183-188]. In combination with age-related penetrance and delayed 
appearance of LVH on echocardiography in adulthood (most often associated with myosin – 
binding protein C defects [183, 184, 189], these novel findings make it no longer possible to 
exclude the diagnosis of HCM in family members solely based on a normal echocardiogram.  
The clinical diagnosis of HCM is most often established with echocardiography, which was 
traditionally found to demonstrate non-dilated LVH in the absence of hemodynamic stresses 
(arterial hypertension, aortic stenosis) or systemic disease (amyloidosis or storage diseases) 
capable of inducing such hypertrophy, regardless of the presence of LV outflow tract 
obstruction [181, 182, 190-195]. However, a substantial overlap is present between 
echocardiographic findings in patients with HCM and those with hypertensive LVH [196-200]. 
Furthermore, it is considered that HCM predominantly affects the heart’s diastolic function 
[201-204], while the systolic properties remain intact (at least in the initial disease period). 
This is mostly due to the assessment of intrinsic function based on volume parameters, such 
as fractional shortening and EF, which often yield 'supra-normal' values of EF in 
hypertrophied ventricles [19, 145, 174, 205-207]. Moreover, these conventional parameters 
only assess global function and concentrate only on radial function, ignoring longitudinal 
function, which in most cardiac pathology is altered before changes occur in radial indices 
[19]. Increased radial function often acts as a compensation for the reduction in global 
longitudinal function [145].  
In a mouse model of familial HCM, cardiac dysfunction (reduced myofibrillar shortening) 
was shown to precede histopathologic changes [209]. Transgenic mice models of HCM have 
shown decreased sarcomere length, systolic shortening and shear strain in segments with 
more pronounced hypertrophy. Myofiber disarray was associated with reduced septal torsion 
and reduced surface shortening [210]. Using regional deformation analysis, these areas of 
histological abnormalities can be easily localized since they do not show any systolic 
deformation, while the rest of the (hypertrophic) segments still deform (although mostly much 
reduced compared to normal) [168, 179, 211-214]. Studies performed to quantify 
deformation in HCM have found a decrease in regional deformation in such patients when 
compared to the control group. However, the localization of fiber disarray areas can vary in 
localization and size among patients with HCM [215, 216]. Recently, it has been shown in 
children with HCM that, despite normal echocardiographic indices of global LV systolic 
function, longitudinal and radial deformation are reduced, where the reduction in deformation 
is inhomogeneous and correlates with the regional pattern of hypertrophy. Furthermore, 
increased post – systolic shortening/lengthening (often found in ischaemic myocardium) and 
delayed mechanical activation were associated with decreased peak systolic deformation in 
the hypertrophic segments, emphasizing the regional nature of myocardial involvement [20, 
217]. A similar pattern of regional deformation was found in a study by Weidemann et al. 
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which describes the “double peak sign” (the second strain – rate peak resulting from post – 
systolic deformation) as a typical deformation pattern seen in hypertrophic segments with 
fibrosis, which was confirmed by CMR LE [218]. Moreover, it has been demonstrated that the 
detection of non-deforming regions, using ultrasonic strain (-rate) imaging allows for easy 
and accurate discrimination between patients with HCM and other forms of hypertrophy 
(hypertension), where the non-deforming regions were most often found in the anterior 
septum and anterior wall (figure 8.5.) [176]. Similar segmental abnormalities were 
demonstrated by circumferential, radial and longitudinal 2D-strain in the septal, anterior 
septal and anterior walls as well [219]. Regional impairment of systolic deformation indices 
was also demonstrated in a DMI study employing strain(-rate) imaging by Kato et al. which 
has shown a correlation between regional systolic strain/strain rate and LV wall thickness in 
patients with HCM, unlike in patients with hypertensive LVH, demonstrating that 
heterogeneity of regional LV systolic function detected by deformation imaging is partly 
attributable to heterogeneity of LVH, suggesting the link to impaired global LV relaxation in 
HCM [220].  
Finally, CMR studies have confirmed the regional pattern of myocardial involvement in 
HCM: CMR tagging data suggest a heterogeneous reduction in shortening and thickening of 
the myocardium which is inversely correlated with end-diastolic wall thickness (reduced 
thickening occurring in HCM patients), while regions of delayed enhancement which 
correspond to tissue with reduced circumferential deformation can be found, such that focal 
nodular enhancement is particularly related with regional dysfunction in patients with HCM 
[221-223].   
Unlike strain/strain–rate indices, which can demonstrate reduced deformation before the 
occurrence of apparent LVH, a study performed in patients with mutations in TNNI3, focal 
fibrosis was not detected by late gadolinium enhancement CMR before LVH and ECG 
abnormalities were present [224].  
 
  
8.7. Amyloidosis  
Amyloid cardiomyopathy can occur within several known forms of systemic diseases – 
amyloidoses [225, 226]. Primary amyloidosis (AL), associated with plasma – cell dyscrasia, 
is the commonest form in which the heart is involved in around 50% of the cases with rapidly 
progressive signs and symptoms of predominantly right heart failure (occurrence of which is 
the worst prognostic factor in this group of patients) [227, 228]. Secondary amyloidosis 
(AA) is increasingly uncommon and typically clinically insignificant [225, 229, 230], while 
hereditary (familial) amyloidosis involves the myocardium, but not as common as AL 
amyloidosis. Hereditary amyloidosis is transmitted as an autosomal dominant disease with 
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an onset predominantly after the age of 40 [225]. It occurs mostly due to transthyretin protein 
mutation which then produces amyloid [231]. Thus, the pattern of cardiac involvement varies 
according to the mutation, while it is generally less aggressive than the AL type. Senile 
systemic amyloidosis results from the deposition of amyloid derived form the wild – type 
transthyretin, invariably presents as congestive heart failure and is linked to a longer median 
survival than the AL type [225, 232, 233]. Isolated atrial amyloidosis is a common finding 
at autopsy, being the only non systemic deposition, limited to the atrium [225, 235, 236].  
Due to widespread amyloid deposits throughout the heart, endomyocardial biopsy is virtually 
100% sensitive in detecting amyloid cardiomyopathy [236, 237]. Regardless of the type of 
amyloidosis, extracellular deposition of amyloid throughout the heart results in biventricular 
wall thickening (rather then hypertrophy), associated with a restrictive pattern detected by 
Doppler echocardiography [225]. Although these findings are typical of end - stage disease, 
diastolic dysfunction can be mildly impaired while its progression suggests progressive 
myocardial infiltration [238].  
It has been shown that amyloid deposits induce oxidant stress that depresses myocyte 
contractile function [239, 240]. Furthermore, amyloid infiltration of the myocardium interrupts 
contractile function which, with progression, can lead to myocyte necrosis and interstitial 
fibrosis, resulting in systolic dysfunction. Conversely, LV ejection fraction assessed by 
conventional echocardiography is considered to remain normal until the late stages of the 
disease. Initial DMI studies were based on pulsed DMI and have demonstrated accuracy in 
detecting the presence of diastolic dysfunction as well as the ability to detect impairment in 
longitudinal systolic function which occurs prior to abnormal LV EF [241, 242]. More recent 
studies implementing strain/strain – rate imaging have confirmed the diffuse pattern of the 
disease (primarily affecting longitudinal function), as well as showing superiority of the 
technique in early detection of impaired LV systolic function: a reduction of longitudinal 
systolic strain in all 16 myocardial segments was shown in patients with systemic AL without 
echocardiographic or Doppler evidence of cardiac involvement. This was reflected in the 
mean systolic strain values of the 6 or even 3 relevant basal segments (basal inferoseptal, 
anteroseptal and posterior segments) as well which were demonstrated as the most accurate 
DMI measurements to differentiate patients with AL with normal echocardiograms from the 
controls [243].  
In line with pathological findings as well as with DMI studies demonstrating diffuse 
myocardial involvement in amyloid cardiomyopathy, CMR studies have shown global 
subendocardial late gadolinium enhancement as well as abnormal myocardial and blood-
pool gadolinium kinetics [244]. The subendocardial/subepicardial involvement leads to a 
severe reduction of the contractility of the longitudinally oriented fibers and results in the 
virtual absence of longitudinal deformation in amyloid cardiomyopathy (figure 8.5.), especially 
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in the basal segments. This is compensated by radial/circumferential shortening, being the 
only deformation generating the cardiac output. 
 
 
8.8. Systemic Diseases 
Although heart involvement in systemic diseases is variable, the evaluation of myocardial 
involvement is important in the initial diagnosis of the disease as well as in disease 
progression monitoring. In diseases for which a specific therapy is available, follow up data 
on the impact of therapy is of high importance [245-247]. However, in subclinical disease 
stages, commonly applied echocardiographic parameters (such as EF calculations) are often 
insensitive to subtle functional impairment [248-250]. Moreover, a later onset of global 
changes which can be detected by routine echocardiography can be anticipated by detecting 
preceding regional changes. Traditionally, metabolic disorders are most often linked with 
concentric hypertrophy [180]. 
Recent research within this group of diseases provides evidence of regional LV 
involvement, detectable by deformation imaging. Even in early stages of disease, signs of 
similar remodelling of the basal “free” LV wall are detectable by reduced systolic deformation 
which may be associated with post-systolic deformation.  
 
Fabry’s disease is an X-linked genetic storage disorder leading to deficient activity of a 
lysosomal enzyme α – galactosidase A, resulting in intracellular, lysosomal accumulation of 
globotriaosylceramide [251]. Despite the severe course of the disease, its rare occurrence 
(estimated incidence of 1:40.000-117. 000 newborn males) and various manifestations often 
lead to misdiagnoses and lengthy inadequate treatment strategies [252]. In these patients, 
cardiac symptoms account for 50-60% of the presenting symptoms, while heart failure is 
among the leading causes of death at an earlier age [253]. This lysosomal storage disorder 
affects the myocytes, leading to LVH (most often concentric hypertrophy in 50% of the 
patients, followed by concentric remodelling in 37%, mostly in younger patients) with 
subsequent systolic and diastolic dysfunction [254, 255]. Deformation imaging data have 
shown a correlation between radial strain rate and myocardial wall thickness, with lower 
strain rate values measured in thicker walls [250]. Furthermore, it has been shown that 
functional abnormalities occur prior to morphologic changes, initially involving the lateral LV 
wall with an impairment of longitudinal systolic function preceding radial dysfunction, thus 
demonstrating a regional (rather than global) nature of myocardial involvement [250]. This 
has been supported by CMR data which demonstrate that fibrosis is initiated in the mid-
myocardial layers of the basal inferolateral wall, combined with reduced strain/strain rate 
values in the involved regions, in which the “double-peak sign” has been described, as a 
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marker of post-systolic thickening [218, 256, 257]. In the end-stage of heart involvement, 
Fabry’s disease is characterized by LVH, myocardial fibrosis (as seen on myocardial biopsy) 
and severely reduced regional LV function [250, 255].  
In the last several years, the availability of specific enzyme replacement treatment has 
focused myocardial imaging studies on the follow up of these patients after enzyme 
replacement therapy, demonstrating both a regression of LVH and an increase of strain rate 
values after one year of therapy [247, 258]. Nevertheless, myocardial segments 
demonstrating LE as seen by CMR have shown no functional improvement during enzyme 
replacement therapy, suggesting that early disease detection and initiation of treatment is 
crucial within this patient population [259].  
 
Friedreich’s ataxia is an autosomal recessive neurodegenerative disease caused by an 
intron GAA triplet repeat expansion, which leads to a gene defect encoding for a 
mitochondrial protein (frataxin), resulting in mitochondrial dysfunction [260]. As a 
consequence, cellular hypertrophy, diffuse fibrosis and focal myocardial necrosis occur [261]. 
Myocardial involvement most often includes concentric or asymmetrical LVH, not affecting 
the right ventricle [248, 262, 263]. An initial DMI study performed by Dutka et al. 
demonstrated reduced systolic and diastolic myocardial velocity gradients in patients with 
Friedreich’s ataxia free of cardiac symptoms [248]. Additionally, an inverse relation between 
the age corrected myocardial velocity gradients and the size of the GAA triple repeat 
expansion was demonstrated in this study, suggesting that abnormal myocardial velocity 
gradients might reflect myocardial involvement as a consequence of the specific genetic 
defect. These findings were followed by a study demonstrating marked reduction of 
myocardial deformation parameters in patients with Friedreich’s ataxia – a marked reduction 
of end-systolic strain and peak systolic strain rate within the hypertrophied myocardium. 
Moreover, impaired systolic and diastolic deformation parameters were present in patients 
with Friedreich’s ataxia without evidence of LVH, as well as in the non-hypertrophied 
segments of patients with regional LVH, suggesting that regional myocardial dysfunction 
precedes changes in LV geometry [255, 263]. Interestingly, the lowest values of systolic 
deformation properties were noted in the basal anterior and lateral LV walls, suggesting a 
similar pattern of regional abnormalities as seen in other systemic diseases as well [263]. 
Recently, it has been shown that an antioxidant drug Idebenone protects mitochondrial 
respiratory dysfunction [264]. In regards to the myocardium, this was confirmed in an initial 
study on eight patients undergoing one year of treatment in which an early linear increase in 
strain rate imaging parameters, reflecting an improvement in cardiac function, was 
demonstrated to precede the reduction of LVH [246].  
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Duchenne muscular dystrophy is an X-linked recessive disease caused by a mutation 
in the dystrophin gene on chromosome Xp21.1,2, resulting in a deficiency of the 
subsarcolemmal protein dystrophin, which is critical for muscle membrane stability [265, 
266]. This disease is clinically associated with skeletal myopathy and dilated 
cardiomyopathy, leading to congestive heart failure and causing death in 30% of these 
patients [267]. A study by Mertens et al employing velocity and deformation analysis, 
performed in young patients with Duchenne muscular dystrophy and normal global systolic 
function, has demonstrated reductions in systolic deformation parameters in  the 
anterolateral and inferolateral LV walls [267], thus confirming similar, regional distribution of 
the affected regions in different systemic diseases (figure 8.5.) 
 
 
8.9. Summary  
Regional deformation analysis in hypertrophic myopathies provides insight to the various 
underlying pathophysiological mechanisms and reveals early, often subclinical impairment in 
systolic function. The combination of detecting the affected myocardial region in conjunction 
with the deformation pattern analysis provides an indicator toward the disease underlying 
hypertrophic remodelling of the ventricle (figure 8.5.). 
The athlete’s heart often comprises hypertrophic remodelling, which in this case, is a 
physiologic form of ventricular adaptation. In such hearts, deformation analysis demonstrates 
normal or even “supranormal” ventricular systolic function.  
In hypertensive heart disease LVH is predominantly localized in the basal septal region, 
where wall stress is highest, resulting in reduced systolic strain values with post-systolic 
shortening. With increasing pressure overload (e.g. aortic stenosis), the neighboring LV 
segments will be affected as well, until irreversible myocyte damage - fibrosis occurs. 
The clinical importance of myocardial involvement in systemic diseases is emphasized by the 
availability of specific therapies. Hypertrophic remodeling is frequently seen in Fabry’s 
disease, Friedreich’s ataxia and Duchenne cardiomyopathy, in which a specific region - the 
basal (infero)lateral segment is most often affected, and which is detectable by reduced 
systolic deformation associated with post-systolic deformation.  
Hypertrophic cardiomyopathy, is associated with regions of local fibre disarray, in which no 
myocardial deformation is present at all, while in the surrounding segments (often showing 
similar thickness), deformation is reduced, but almost normal compared to normal hearts. 
The absence of deformation is mostly associated with the thickest segments. Depending on 
the individual patient, these regions can be located anywhere within the ventricles, but are 
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most often localized in the interventricular septum where the basal-mid segment reveals total 
absence of longitudinal deformation, while radial function is still preserved.  
Unlike the aforementioned diseases in which myocardial involvement is regional, amyloidosis 
seems to provide an exception in which the impairment of systolic function affects the 
myocardium globally (although with slightly more involvement in the basal regions compared 
to the apical). Amyloid cardiomyopathy presents with global LVH and diffuse, severe 
reduction (and even absence) of longitudinal strain, while the radial strain is still preserved, 
but of low values.  
Figure 8.5. provides a schematic overview of basic substrates of hypertrophic remodelling as 
well as the pertaining longitudinal strain curves, as described above. Note that the 
longitudinal strain y-scale is equally set in all examples, thus providing more consistent 
information on the scale of deformation abnormalities.  
 
 
Figure 8.5. Schematic overview of basic substrates of hypertrophic remodelling and the 
pertaining longitudinal strain curves.  
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8.10. Conclusion 
While all hypertrophic myopathies show thickening of the myocardial walls, they clearly 
represent a heterogeneous group of diseases with a wide spectrum of myocardial 
involvement. This heterogeneity can be appreciated from the microscopic level, to specific 
myocardial regions affected by the underlying disease (Table 8.1, figure 8.5.).  
By the introduction of deformation imaging in clinical practice, a novel insight to regional 
myocardial function has been provided; since then, multiple studies provided clinical data 
which support the regional nature of these myopathies, frequently emphasizing the 
significance of induced abnormal systolic function. Furthermore, the assessment of 
longitudinal myocardial function proves to be of high importance: the assessment of radial 
function, which is routinely performed, might mask the early onset of functional impairment 
which most often primarily affects the longitudinal myocardial fibers. Moreover, regional 
phenomena such as post-systolic thickening/shortening may occur in several of these 
diseases (arterial hypertension, Fabry’s disease), in which case the localization of the 
affected segment might point toward the underlying substrate.  
Therefore, the assessment of systolic function in hypertrophic myopathies must not be 
deemed secondary to the assessment of diastolic (dys)function, these data should rather be 
integrated in a comprehensive approach to hypertrophic remodelling and early detection of 
myocardial functional impairment.  
 
 
 Biopsy Regional/
global 
Affected 
region 
Deformation Longitudinal/ 
Radial 
dysfunction 
Diastolic 
function 
Athletes Normal Global Diffuse (Supra)normal - (Supra)normal
 
Pressure 
overload 
Cellular 
hypertrophy 
Regional Basal 
septum 
Reduced + 
PST 
Longitudinal Impaired 
HCM Myocyte 
disarray 
Regional Basal 
septum 
Absent  Longitudinal Impaired 
Amyloidosis Extracellular 
amyloid deposit 
Global Diffuse Severely 
reduced 
Longitudinal, 
less radial 
Impaired – 
pseudonormal
Systemic 
diseases 
Cellular 
hypertrophy 
Regional Basal 
inferolateral
PST Longitudinal, 
less radial 
Impaired 
 
Table 8.1. Typical biopsy findings and characteristics of deformation parameters and 
diastolic function in the early stages of different types of hypertrophic remodelling.  
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Chapter 9 
Summary 
 
 
In contemporary clinical cardiology practice, echocardiography plays a leading role in the 
diagnosis and management guidance of various forms of myocardial remodelling. 
Furthermore, it is the most commonly used diagnostic technique in the elucidation of the 
underlying substrates and pathophysiologic mechanisms of heart failure as a consequence 
of ventricular remodelling. Due to its widespread availability, non-invasiveness, user-
friendliness and relatively low cost, echocardiography is still irreplaceable by other cardiac 
imaging methods which should rather be seen as complementary diagnostic tools.   
This thesis sought to study several types of ventricular remodelling and their 
consequences on regional and global myocardial function, employing different 
echocardiographic tools and dedicated signal and image analysis algorithms in the detection 
of ventricular dysfunction.  
Recent echocardiographic techniques based on Myocardial Velocity Imaging have 
provided the possibility of a more detailed and integrated insight to cardiac (dys-) function. 
Based on novel understandings, we first gave an original integrated overview on ‘cardiac 
function’, distinguishing intrinsic myocyte function (often referred to as contractility) and 
ventricular pump function as well as the main components of function, namely force 
development and deformation. Additionally, the boundary conditions in which the heart 
functions, which determine the interactions between these components were defined as: a) 
wall properties such as tissue composition/elasticity, fibre structure and global geometry, and 
b) interaction between the heart and peripheral circulation, mostly described as (pressure & 
volume) loading conditions. 
Furthermore, Doppler echocardiography data were analyzed in a study addressing flow 
remodelling as a consequence of cellular and force remodelling in ischaemically remodelled 
hearts. A dedicated automated quantification of the CW outflow Doppler traces was used to 
define specific trace parameters indicative of myocardial dysfunction. It was shown that 
decreased overall contractility results in a more symmetrical outflow velocity profile, which 
would suggest that the global development of contractile force has been remodelled to cope 
with the decreased output resulting from decreased contractility. 
Similar automatic quantification of the aortic instantaneous peak velocities was further 
employed in patients with hypertrophic remodelling due to aortic stenosis. This study has 
shown that the values of trace asymmetry before surgery are predictive of the change in EF 
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pre- and postoperatively: all of the patients with markedly symmetric preoperative 
instantaneous peak velocities showed stagnation or deterioration of EF postoperatively. 
Furthermore, the study has proven that the symmetry of the shape of the instantaneous peak 
velocities is a more reliable predictor of functional improvement after the valve replacement 
procedure as compared to mean aortic gradient and aortic valve area which are widely used 
in preoperative assessment of patients with aortic stenosis. 
An intraoperative Doppler myocardial imaging study was performed along with standard 
echocardiography in an analysis of electrical remodelling in patients with LBBB during the 
CRT implantation procedure. In addition to confirming the septal flash as a mechanical 
consequence of the underlying electrical problem and a valid marker of intraventricular 
dyssynchrony, an acute contractility recruitment, resolution of the septal flash as well as 
reverse remodelling immediately following CRT device activation was shown in these 
patients. 
As opposed to remodelling induced by changes in loading conditions, evidence of 
hypertrophy and hypercontractility without an additional change in afterload resulting in 
increased cardiac output and inducing additional signs of vascular remodelling was 
demonstrated in patients with early stage acromegaly.  
Finally, a comprehensive view on the changing role of echocardiography in the diagnosis 
of hypertrophic myopathies is presented. Previous knowledge as well as regional 
deformation data (including deformation pattern analysis) are combined to provide an 
indicator toward the disease underlying hypertrophic ventricular remodelling: in hypertensive 
heart disease LVH is predominantly localized in the basal septal region showing reduced 
systolic strain values with post-systolic shortening; systemic diseases such as Fabry’s 
disease often affect a specific region - the basal (infero)lateral segment in which post-systolic 
deformation is often present. Hypertrophic cardiomyopathy is associated with regions of local 
fibre disarray, in which no myocardial deformation is present at all, while in the surrounding 
segments (often showing similar thickness) deformation is reduced, but almost normal as 
compared to undiseased hearts. The absence of deformation is mostly associated with the 
thickest segments. Amyloidosis seems to provide an exception in which the impairment of 
systolic function affects the myocardium globally – it is presented with global LVH and 
diffuse, severe reduction of longitudinal strain, while the radial strain is still preserved, but of 
low values.  
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Ispitivanje regionalne i globalne morfologije te funkcije miokarda u 
različitim oblicima srčanog remodeliranja  
Sažetak 
 
U suvremenoj kardiologiji ehokardiografija ima vodeću ulogu u dijagnostici i odabiru 
postupaka u raznim oblicima remodeliranja miokarda. Nadalje, to je najčešće primjenjivana 
metoda u rasvjetljavanju temeljnih supstrata i patofizioloških mehanizama zatajenja srca kao 
posljedice remodeliranja klijetki. Zahvaljujući širokoj dostupnosti, neinvazivnosti, lakoći 
primjene i relativno malenoj cijeni, ehokardiografija je i dalje nezamjenjiva u odnosu na druge 
metode oslikavanja u kardiologiji, koje bi valjalo prihvatiti kao komplementarne dijagnostičke 
metode. 
Cilj je ove disertacije istražiti nekoliko oblika remodeliranja klijetki i njihovih posljedica na 
regionalnu i globalnu funkciju miokarda, primjenom različitih ehokardiografskih metoda i 
specifičnih algoritama analize signala i slike u otkrivanju disfunkcije srca.  
Novije ehokardiografske tehnike temeljene na oslikavanju miokardnih brzina gibanja 
(Myocardial Velocity Imaging) omogućuju podrobniji i integrirani pogled u (dis)funkciju srca. 
Na temelju novijih spoznaja, na početku disertacije prikazan je originalni, integrirani pregled 
„srčane funkcije“, razlikujući intrinzičnu funkciju miocita (obično nazivanu kontraktilitetom)  i 
crpnu funkciju klijetki, kao i glavne sastojnice srčane funkcije, to jest razvoj sile i deformaciju., 
Uvjeti u kojima srce radi, koji određuju odnos između navedenih sastavnica, definirani su 
kao: a) svojstva stijenke poput građe/elastičnosti tkiva, strukture vlakna i globalne geometrije, 
te b) interakcija srca i periferne cirkulacije koja se većinom opisuje kao stanje punjenja 
(tlačno i volumno opterećenje).      
U ispitivanju remodeliranja protoka kao posljedici staničnog remodeliranja i remodeliranja 
sile u ishemijski remodeliranom srcu, obrađivali smo podatke Dopplerske ehokardiografije. 
Posebna automatska kvantifikacija Dopplerskih zapisa istiska lijeve klijetke primijenjena je u 
definiranju specifičnih svojstava krivulje, koja ukazuju na disfunkciju miokarda. Dokazali smo 
da smanjenje ukupne kontraktilnosti uzrokuje simetričniji oblik krivulje istiska lijeve klijetke, 
što sugerira remodeliranje globalne kontraktilne sile, kako bi se prilagodila smanjenju istiska 
zbog smanjene kontraktilnosti.  
Slična automatska kvantifikacija trenutnih vršnih brzina protoka kroz aortni zalistak 
primijenjena je i u bolesnika s hipertrofijskim remodeliranjem klijetki u aortnoj stenozi. Ovo 
istraživanje pokazalo je da predoperativne vrijednosti asimetrije Dopplerskog zapisa 
predskazuju poslijeoperacijsku promjenu ejekcijske frakcije: u svih bolesnika sa značajno 
simetričnim predoperativnim vršnim brzinama kroz aortni zalistak dokazali smo pogoršanje ili 
 114
istovjetnu ejekcijsku frakciju nakon operacije. Nadalje, ovo je istraživanje dokazalo da je 
simetričnost vršnih brzina pouzdaniji predskazatelj  funkcijskog oporavka nakon zamjene 
aortnog zalistka, u usporedbi sa srednjim transaortnim gradijentom i površinom aortnog ušća 
koji se često koriste u predoperativnoj evaluaciji bolesnika s aortnom stenozom.  
U analizi električnog remodeliranja u bolesnika s blokom lijeve grane, provedeno je, uz 
standardnu ehokardiografiju, intraoperacijsko ispitivanje miokardnog Dopplera tijekom 
postupka ugradnje resinkronizacijskog elektrostimulatora. Uz potvrdu flash - septuma kao 
mehaničke posljedice temeljnog električnog problema te valjanog pokazatelja 
intraventrikulske disinkronije, u ovoj skupini bolesnika dokazano je i akutno poboljšanje 
kontraktilnosti, nestanak flash - septuma kao i povratno remodeliranje lijeve klijetke 
neposredno nakon uključivanja resinkronizacijskog elektrostimulatora.   
Za razliku od remodeliranja uzrokovanog promjenom uvjeta punjenja, u skupini bolesnika 
s akromegalijom dokazali smo hipertrofiju i hiperkontraktilnost lijeve klijetke uz posljedično 
povećanje minutnog volumena srca te razvoj znakova vaskularnog remodeliranja, bez 
dodatnih promjena u tlačnom opterećenju srca. 
Disertacija završava širim prikazom izmijenjene uloge ehokardiografije u dijagnozi 
hipertrofijskih bolesti miokarda. Prethodna saznanja kao i podatci o regionalnoj deformaciji 
(uključujući analizu uzoraka deformacije) povezani su u svrhu prepoznavanja bolesti koja je u 
podlozi hipertrofijskom remodeliranju klijetki: u hipertenzivnoj bolesti srca hipertrofija je 
većinom lokalizirana u bazalnom interventrikulskom septumu uz smanjenje vrijednosti 
sistoličkog strain-a te nastanak post-sistoličkog izduljenja. Sistemske bolesti poput Fabryjeve 
bolesti često zahvaćaju određenu regiju srca – bazalni (infero)lateralni segment u kojem je 
često prisutno post-sistoličko zadebljanje. Hipertrofijska kardiomiopatija je povezana s 
ograničenim područjima poremećene arhitekture srčanih vlakana, u kojima je deformacija u 
potpunosti odsutna, dok je u okolnim segmentima (često slične debljine stijenke) deformacija 
smanjena, no gotovo normalna. Odsutnost deformacije obično je povezana s 
najzadebljanijim segmentima. Čini se da amiloidoza predstavlja iznimku u kojoj smanjenje 
sistoličke funkcije globalno zahvaća miokard - nalazi se globalna hipertrofija lijeve klijetke te 
difuzno, teško oštećenje logitudinalnog straina dok je radijalni strain još očuvan, ali malenih 
vrijednosti.  
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